

CURRICULUM VITAE

Date prepared: March 28th, 2024

NAME: Zbigniew (Ziggy) Macdonald Szczepiorkowski

ADDRESS:

Office

Transfusion Medicine Service
Department of Pathology and Laboratory Medicine
One Medical Center Drive

Lebanon, NH 03756

Phone: (603) 650-7171

Fax: (603) 650-4845

E-mail: Zbigniew.M.Szczepiorkowski@hitchcock.org

E-mail 2: ziggy@dartmouth.edu

I. EDUCATION:

<u>DATE</u>	<u>INSTITUTION</u>	<u>DEGREE</u>
1984	St. Augustine's Lyceum, Warsaw, Poland	BS equivalent (Major in Mathematics and Physics with Honors, Ranked 2 nd in a class of 100)
1991	Warsaw Medical University, Warsaw, Poland	MD (Magna cum laude, Ranked 3 rd in a class of 156)
1997	Postgraduate Center of Medical Education, Warsaw, Poland	PhD (Medicine)

II. POSTDOCTORAL TRAINING

<u>DATE</u>	<u>INSTITUTION</u>	<u>SPECIALTY</u>
1990	Massachusetts General Hospital, Boston, MA	Visiting Research Fellow, Pathology
1991 – 1992	Postgraduate Center of Medical Education, Mokotowski Hospital, Warsaw, Poland	Intern in Combined Internship Program (Internal Medicine, Ob-Gyn, Surgery and Pediatrics)
1992 – 1995	Massachusetts General Hospital, Boston, MA	Department of Pathology, Research Fellow,
1995 – 1997	Massachusetts General Hospital, Boston, MA	Clinical Pathology, Resident
1997	Massachusetts General Hospital, Boston, MA	Clinical Pathology, Chief Resident
1997 – 1998	Massachusetts General Hospital, Boston, MA	Blood Banking/Transfusion Medicine, Grove Rasmussen Fellow The Harvard Medical School Fellowship Program in Transfusion Medicine

III. PROFESSIONAL DEVELOPMENT ACTIVITIES

<u>DATES</u>	<u>INSTITUTION</u>	<u>TITLE</u>	<u>CREDITS</u>
N/A			

IV. ACADEMIC APPOINTMENTS

<u>DATE</u>	<u>INSTITUTION</u>	<u>TITLE</u>
1992 – 1995	Harvard Medical School, Boston, MA	Research Fellow
1995 – 1998	Harvard Medical School, Boston, MA	Clinical Fellow
1998 – 2006	Harvard Medical School, Boston, MA	Instructor in Pathology
2003 – 2006	Dartmouth Medical School, Hanover, NH	Assistant Professor of Pathology and of Medicine
2006 – 2019	Geisel School of Medicine at Dartmouth, Hanover, NH	Associate Professor of Pathology and of Medicine
2019 - present	Geisel School of Medicine at Dartmouth, Hanover, NH	Professor of Pathology and Laboratory Medicine; Professor of Medicine

V. INSTITUTIONAL LEADERSHIP ROLES:

<u>DATE</u>	<u>INSTITUTION</u>	<u>TITLE</u>
2003 – 2004	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Co-Director, Blood Bank and Transfusion Service
2003 – 2004	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Director, Cell Processing Laboratory, Dept. of Pathology
2004 – present	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Director, Cellular Therapy Center, Dept. of Pathology
2004 – present	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Medical Director, Transfusion Medicine Service, Dept. of Pathology & Lab Medicine
2008 – 2016	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Medical Director, Cell Labeling Laboratory, Dept. of Pathology
2008 – present	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Director, Transfusion Medicine Fellowship Program
2010 – 2013	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Associate Director, Pathology Residency Program
2010 – 2016	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Medical Director, Center for Transfusion Medicine Research
2010 – present	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Section Chief, Laboratory Medicine /Clinical Pathology / Laboratory Medicine
2011 – 2015	Geisel School of Medicine at Dartmouth, Hanover, NH	Elected Member, Faculty Council
2014 – 2020	Center for Synthetic Immunity, Geisel School of Medicine at Dartmouth, Hanover, NH	Scientific Advisory Board
2016 – present	Dartmouth-Hitchcock Medical Center, Lebanon, NH	Director, Transfusion Medicine Research Center (aka Cell Labeling Laboratory), Dept. of Pathology and Laboratory Medicine

VI. LICENSURE AND CERTIFICATION (IF APPLICABLE):

<u>DATE</u>	<u>LICENSURE/CERTIFICATION</u>
1992	Medical License, Poland
1993	FLEX Component 1 and 2
1998 – present	Medical License, Massachusetts, # 154 167, expires 05/11/2025
1999 – present	Clinical Pathology, The American Board of Pathology
2000 – present	Blood Banking/Transfusion Medicine, The American Board of Pathology
2003 – present	Medical License, New Hampshire, # 12041, expires 06/30/2025

VII. HOSPITAL APPOINTMENTS:

<u>DATES</u>	<u>INSTITUTION</u>	<u>POSITION/TITLE</u>
1998 – 2002	Massachusetts General Hospital, Boston, MA	Assistant in Pathology, Dept. of Pathology
2002 – 2003	Massachusetts General Hospital, Boston, MA	Assistant Pathologist, Dept. of Pathology
2003 – present	Massachusetts General Hospital, Boston, MA	Consultant, Dept. of Pathology
2003 – present	Mary Hitchcock Memorial Hospital, Lebanon, NH	Active Clinical Staff, Pathology and Laboratory Medicine; Department of Medicine
2004 – present	Dartmouth Cancer Center, Lebanon, NH	Investigator
2015 – present	Valley Regional Hospital, Claremont, NH	Provisional Active Staff (Surgery)
2015 – present	Alice Peck Day Memorial Hospital, Lebanon, NH	Associate Staff

VIII. OTHER PROFESSIONAL POSITIONS (NON-DARTMOUTH):

<u>DATES</u>	<u>INSTITUTION</u>	<u>POSITION/TITLE</u>
1998 – 2000	Massachusetts General Hospital, Boston, MA	Assistant Director, Blood Transfusion Service
2000 – 2003	Massachusetts General Hospital, Boston, MA	Associate Director, Blood Transfusion Service
2000 – 2003	Partners AIDS Research Center, Boston, MA	Director, MGH Immunotherapy Laboratory
2002 – 2003	Massachusetts General Hospital, Boston, MA	Laboratory Director, Bone Marrow Processing Laboratory, MGH Bone Marrow Transplantation Program, Dept. of Medicine
2000 – present	Foundation for the Accreditation of Cellular Therapy	Inspector for Collection and Processing Facilities (38 inspections)
2003 – present	National Marrow Donor Program	Director, Apheresis Center
2008 – 2009	Fenwal, Inc.	Scientific Advisory Board
2010 – 2015	National Marrow Donor Program	Director, Board of Directors

2010 – present	Fenwal, Inc. / Fresenius Kabi	Scientific Advisory Board
2011 – 2014	National Blood Foundation RET	Trustee, Board of Trustees
2013 – 2022	Grifols, Inc.	Medical Consultant
2014 – 2016	World Apheresis Association	Treasurer, Board of Directors
2016 – 2019	Institute of Hematology and Transfusion Medicine, Warsaw, Poland	Visiting Professor
2017 – 2018	National Blood Foundation RET	Trustee, Board of Trustees
2019 – present	ICCBBA, Inc	Director, Board of Directors
2019 – 2022	Grifols, Inc	Scientific Advisory Board – AMBAR
2019 – present	Institute of Hematology and Transfusion Medicine, Warsaw, Poland	Consultant
2020 – 2022	ICCBBA, Inc	Treasurer, Board of Directors
2022- 2023	ICCBBA, Inc	Vice Chair, Board of Directors
2023- present	ICCBBA, Inc	Chair, Board of Directors

IX. TEACHING ACTIVITIES:

Please append course reviews or other metrics (e.g., eVal) with your CV.
See attachment A

A. UNDERGRADUATE (COLLEGE) EDUCATION

NOT APPLICABLE

B. GRADUATE EDUCATION (List classes taught for Ph.D. and Masters students):

<u>DATES</u>	<u>INSTITUTION</u>	<u>NAME OF COURSE/ACTIVITY</u>	<u>ROLE</u>	<u>FREQUENCY</u>	<u>HOURS</u>
1998	Northeastern University	Microbiology, “Retroviruses”	Lecturer		8
2001	Northeastern University	Medical Bacteriology, “Transfusion transmitted bacterial infections”	Lecturer		8

C. UNDERGRADUATE MEDICAL EDUCATION (Inclusive of both classroom teaching and medical student instruction in clerkships):

1985-1987	Teaching Assistant/ Tutor – Human Anatomy 15-20 Medical Students	Warsaw Medical School, Warsaw, Poland Responsible for Administration of 10 tests/year; 360 hours per year
-----------	---	--

1996-2003	Lecturer – Medicine, HMS III, Transfusion Medicine – An Overview 20-25 Medical Students	Harvard Medical School 16 hours per year
1998	Instructor, Laboratory part of course in Immunology, Microbiology and Infectious Diseases 20-25 Medical Students	Harvard Medical School 20 hours
1999-2003	Examiner, Objective Structured Clinical Examination (OSCE), Pathology Station 20 Medical Students	Harvard Medical School 8-12 hours per year
1999-2003	Lecturer, Pathology Course, Laboratory Medicine – Transfusion Medicine 30 Medical Students	Harvard Medical School 5 hours per year
2003-2006	Tutor/ Minicase Leader, Hematology Course 12 Medical Students	Harvard Medical School 12 hours per year
2003-2006	Lecturer, SBM Hematology – Transfusion Medicine lecture 80 Medical Students	Dartmouth Medical School 1-hour lecture per year
2004-present	Faculty, Pathology elective – Transfusion Medicine Rotation 1-2 Medical Students per rotation	The Geisel School of Medicine at Dartmouth 1-5 times per year; 30-40 hours per year
2007-2009	Lecturer, SBM Hematology – Transfusion Medicine lecture 80 Medical Students	Dartmouth Medical School One 2-hour lecture per year
2010-2019	Lecturer, SBM Hematology – Transfusion Medicine lecture 90 Medical Students	The Geisel School of Medicine at Dartmouth 1-hour lecture per year

D. GRADUATE MEDICAL EDUCATION (Inclusive of instruction of residents and fellows during clinical practice):

1996 – 1998	Lecturer, Clinical Pathology Lecture Series in Hematology 2-4 1 st and 2 nd year Pathology Residents	Massachusetts General Hospital 96 hours per year
1998 – 2003	Clinical Pathology Lecture Series in Transfusion Medicine 2-4 1 st and 2 nd year Pathology Resident; 1 TM Fellow	Massachusetts General Hospital Eight x hour lectures every 4 months
1999 – 2003	Medical Intensive Care Unit Lectures	Massachusetts General Hospital

	10-12 1 st and 2 nd year Medicine Residents	Four x hour lectures per year
2003 – 2006	Clinical Pathology 2-4 1 st and 2 nd year Pathology Resident; 1 TM Fellow	Massachusetts General Hospital Three x hour lectures every 4 months
2003 – 2008	Intensive Care Unit, Transfusion Medicine 10-14 1 st and 2 nd year Medicine, Surgery and Anesthesia residents; ICU fellows	Dartmouth-Hitchcock Medical Center 6 hours per year (monthly lectures shared with Dr. AuBuchon)
2003 – present	Pathology Elective for Anesthesiologists, Transfusion Medicine 3-6 1 st year Anesthesia Residents	Dartmouth-Hitchcock Medical Center 2-4 hours (year dependent)
2004 – present	Clinical Pathology, lectures in Transfusion Medicine 3-4 2 nd year Pathology Residents	Dartmouth-Hitchcock Medical Center 4-6 hours
2005	Surgery, Transfusion Medicine 15 1 st and 2 nd year Surgery Residents	Dartmouth-Hitchcock Medical Center One-hour lecture
2006-2020	Vascular Surgery, Coagulation and Transfusion Medicine 10-14 1 st , 2 nd and 3 rd year surgery resident; vascular fellows; faculty	Dartmouth-Hitchcock Medical Center One hour per year
2007-present	Clinical Pathology 2-4 1 st and 2 nd year Pathology Resident; 1 TM Fellow	Massachusetts General Hospital One hour repeated every 3 months
2008-2020	Hematology-Oncology Fellowship Lecture Series 4-6 1 st , 2 nd and 3 rd year heme-onc fellows	Dartmouth-Hitchcock Medical Center 2-3 lectures (2 hours) per year
2008-2011	Intensive Care Unit, Transfusion Medicine 10-14 1 st and 2 nd year Medicine, Surgery and Anesthesia residents; ICU fellows	Dartmouth-Hitchcock Medical Center One hour monthly; 12 hours per year
2010-2019	Internal Medicine, Transfusion Medicine 15-20 1 st year medicine residents	Dartmouth-Hitchcock Medical Center Once a year and once every 3 years (1-2 hours)(two lectures)

E. OTHER CLINICAL EDUCATION (e.g., PA programs)

NONE

X. ADVISING/MENTORING

A. UNDERGRADUATE STUDENTS

B. GRADUATE STUDENTS

C. NON-DEGREE PROGRAM STUDENTS (e.g., certificate programs, post-baccalaureate programs)

D. MEDICAL STUDENTS

E. RESIDENTS/FELLOWS

- 2006 – 2011 Erin K. Meyer, MD, MPH / Medical Director, Nationwide Children’s Hospital
Career stage: AP/CP Resident *Mentoring role:* residency advisor in TM
Accomplishments: Multiple publications, fellowship at Harvard Medical School
- 2007 – 2011 Justin D. Kreuter, MD / Medical Director TM, Mayo, Rochester MN
Career stage: AP/CP Resident *Mentoring role:* residency advisor in TM
Accomplishments: Multiple publications, fellowship in TM at Mayo
- 2008 – 2009 James D. Gorham, MD, PhD / Section Chief, University of Virginia
Career stage: fellow. *Mentoring role:* fellowship mentor *Accomplishments:* publications and setting up career in clinical transfusion medicine
- 2009 – 2010 Maria Teresa Bejarano, MD / Med Oncologist, Brigham and Women’s Hospital
Career stage: fellow. *Mentoring role:* fellowship mentor *Accomplishments:* publications and support in selecting fellowship in heme-onc
- 2010 – 2011 Melissa L. Petras, MD / Attending in TM; Quality, University of Buffalo
Career stage: resident, fellow. *Mentoring role:* fellowship mentor
Accomplishments: publications and support in identifying the best career pathway
- 2011 – 2012 Litchia Pinheiro Weber, MD / Physician, North Stamford Medical Associates
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* publications, platform presentations at ASFA and successful support in obtaining hospitalist position at our institution
- 2012 – 2013 Swaroopa Yerrabothala, MD / Asst Professor, Dartmouth Hitchcock Med Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications, and successful support in obtaining heme-onc fellowship position at our institution
- 2013 – 2014 Mathew Katus, MD / Pathologist, Arrowhead Regional Medical Center, Colton, CA
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications, and successful support in obtaining faculty position
- 2014 – 2015 Purva Sharma, MD / Fellow Heme-Onc, Univ of Vermont Medical Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications, including a book chapter, and successful in obtaining fellowship appointment at University of Vermont Medical Center;
- 2015 – 2016 Caroline Alquist, MD, PhD / Medical Director, TM, Ochsner Clinic
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications and successful in obtaining faculty position at Ochsner Clinic and professional involvement at AABB; best poster award at ASFA

- 2016 – 2017 Isabella Martin, MD / Director Microbiology, Dartmouth-Hitchcock Medical Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications and successful promotion to Medical Director of Microbiology
- 2017 – 2018 Reggie Thomasson, MD / Director, TM, Boston Medical Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications and successful in obtaining faculty position at BMC
- 2018 – 2019 Luke Plumier, MD / Attending, TM, Bilings Clinic, Montana
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Publications in preparation and successful in obtaining faculty position.
- 2019 – 2020 Jenna Khan, MD / Fellow, TM Dartmouth-Hitchcock Medical Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Faculty position at DHMC; publications
- 2020 - 2021 Kristen Ruby, DO / Fellow, TM Dartmouth-Hitchcock Medical Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* Faculty position at MGH; publications.
- 2022 – 2023 Freddy Nguyen, MD, PhD / Fellow, TM Dartmouth-Hitchcock Medical Center
Career stage: fellow. *Mentoring role:* fellowship advisor. *Accomplishments:* .
- 2023- present Regina M. DelBaugh, DO, MS / Fellow, TM Dartmouth-Hitchcock Medical Center;
Career stage: fellow, *Mentoring role:* fellowship advisor.
Accomplishments: publications; position at VCU

F. FACULTY

- 2010 – present Nancy M. Dunbar, MD / Assoc Prof, Dartmouth-Hitchcock Medical Center
Career stage: faculty. *Mentoring role:* faculty advisor *Accomplishments:* publications and prominent role in the field of transfusion medicine nationally and internationally
- 2020 – 2022 Jenna Khan, MD / Asst Prof, Dartmouth-Hitchcock Medical Center
Career stage: faculty. *Mentoring role:* faculty advisor *Accomplishments:* publications;

G. ADDITIONAL INFORMATION

CONTINUING MEDICAL EDUCATION:

<u>DATES</u>	<u>NAME OF COURSE/ACTIVITY</u>	<u>ROLE</u>	<u>FREQUENCY</u>	<u>HOURS</u>
2001	AABB/ISHAGE Audioconference, Cord Blood Transplantation	Lecturer	Once	
2002	AABB Audioconference, 3 rd edition of HPC Standards	Lecturer	Once	

2005	AABB Audioconference, 1 st edition of Cellular Therapy Standards	Lecturer	Once	
2007	AABB Audioconference, 2 nd edition of Cellular Therapy Standards	Lecturer	Once	
2007	AABB Audioconference, ASFA/Cellular Therapy Topics	Lecturer	Once	
2007	ASCP Audioconference, Stem Cell Collections – The Newest Blood Bank Component	Lecturer	Once	
2008	Therapeutic Apheresis in Nephrology	Lecturer	Once	1.5
2009	AABB Audioconference, BEST Collaborative and Cellular Therapy	Lecturer	Once	
2009	Therapeutic Apheresis in Rheumatology, Rheumatology GR	Lecturer	Once	1
2009	Blood Safety in the US (Delegation from Kyrgyzstan)	Lecturer	Once	1
2010	ASFA Audioconference, New Apheresis Guidelines	Lecturer	Once	
2019	AABB Webinar	Lecturer	Once	1
///	/// update			

Multiple lectures in 2019 – 2024.**XI. RESEARCH TEACHING/MENTORING****A. UNDERGRADUATE STUDENTS****B. GRADUATE STUDENTS****C. MEDICAL STUDENTS****D. RESIDENTS/FELLOWS/RESEARCH ASSOCIATES**

I have developed research projects with several of our trainees both at Dartmouth and Massachusetts General Hospital as well as research associates and healthcare providers. The list below excludes Transfusion Medicine Fellows and Faculty who are listed above.

Residents:

Eichbaum, QG

Agrawal, YP

Best, CA

Greene, MR

Linnik, YA

Ruby, KN

Meyer, EK Dr. Meyer received the best abstract in neurology 2007 and presented during the abstract plenary session.

Kreuter, Justin

Scott, SM

Technologists:

Bushnell, KM

Webber, S

Nurses:

Dobrusin, I

Ritzenthaler, J

Pavelka, MJ

Weber, SM

Klinker, K

McGregor, DJ

Didehbani, TS

Maynard, KJ

Martin, CLB

Undergraduate:

Walsh, SJ

E. FACULTY

XII. COMMUNITY SERVICE, EDUCATION, AND ENGAGEMENT:

XIII. RESEARCH FUNDING:

A. CURRENT SUPPORT

2022-ongoing Cellphire, Inc
Site Contributor

B. PAST SUPPORT

- 2002-2003 In-vivo induction of HIV specific CTL by dendritic cells
NIH 5 R01 A144628-04
Consultant (PI: N. Bhardwaj)
The last part of this multi-year project was to generate autologous dendritic cells from the patients who received HAART at the acute phase of HIV infection. The dendritic cells, cultured from the patient's monocytes, were then exposed to selected peptides, matured and injected to the patients. The immune responses were monitored.
- 2003 - 2004 Dendritic cell vaccine therapy in melanoma
Hitchcock Foundation Grant
Co-Investigator (PI: M. Ernstoff)
The primary goal of this study was to investigate patients' response to autologous dendritic cells exposed to patient's tumor lysate obtained from metastases. This "cancer vaccine" was used in parallel to patient's primary treatment.
- 2003 - 2008 Immunotherapy of renal cell carcinoma
NIH 1 R01 CA095648
Co-Investigator (PI: M. Ernstoff)
In this study the primary objective as to investigate combined immunotherapy of high dose IL-2 with autologous dendritic cells exposed to tumor lysate obtained from patient's primary tumor. The primary outcome was survival and disease recurrence
- 2003-2010 Cellular Therapy Products, exploratory in vitro studies
Department of Pathology, DHMC
Principal Investigator
The funding provided support for several in vitro studies related to culture and storage of dendritic cells, lymphocytes and monocytes. Funding also supported studies performed in the context of the BEST Collaborative.
- 2005-2007 Randomized sham-controlled trial of column treatment in Crohn's disease
Otsuka
Site Co-Principal Investigator
This was phase III randomized controlled trial with sham apheresis procedures performed in the control arm evaluating safety and effectiveness of the Adacolumn device. The objective of this study was to utilize granulocyte column manufactured by Otsuka in the patients with moderate Crohn's disease as the secondary therapy.
- 2005-2008 Lymphodepletion and Adoptive Immunotherapy for Transplanted Myeloma Patients
Leukemia & Lymphoma Society (6061-06) (2005-2008)
Co-Investigator (PI: K. Meehan)

The goal of this study was to evaluate the response of patients with myeloma who received autologous transplant to autologous expanded lymphocytes. The immune response as well as overall survival were studied.

- 2007 - 2008 US, Clinical evaluation of cymbal unfiltered with PVC container storage
Haemonetics Corp
Co-Investigator (PI: L. Dumont)
This study evaluated a new blood collection device in the population of healthy subjects. The red blood cell survival and recovery in combination with other in vitro factors were evaluated. The results of this study served as the scientific support for 510k application to FDA.
- 2007 - 2010 The use of dendritic cell vaccine in patients with glioblastoma multiforme.
Family Foundation
Co-Investigator (PI C. Fadul)
The goal of this study was to generate autologous dendritic cells which were primed with the tumor lysate from patients with GM. The cells were injected into the neck lymph nodes and their impact on disease progression studied.
- 2007 - 2012 Validation of Methods for Platelet Cryopreservation, Storage and Reconstitution and Validation of In vivo Survival of Cryopreserved Platelets
US Army Medical Material Development Program
Co-Investigator (PI: L. Dumont)
The primary goal of this study was to show that platelets can be successfully cryopreserved and thawed with clinically relevant survival in the circulation of healthy subjects. This was the primary study which led to clinical studies in the use of cryopreserved platelets.
- 2008 - 2009 Mesenchymal stem cells in Crohn's disease
Osiris
Site Co- Investigator (PI: G.Levine)
This study looked focused on the use of allogeneic mesenchymal stem cells in the patients with mild to moderate Crohn's disease. The manufacturer of the cells, Osiris Therapeutics later acquired by Mesoblast, provided the product which was then injected to our patients. The clinical outcomes were followed.
- 2008 - 2010 BEST 25 Buffy Coat Platelets
BEST & Department of Pathology
Co-Investigator (PI: L. Dumont)
A recent review concluded that there was inadequate evidence to show a difference between buffy coat (BC) and platelet (PLT)-rich plasma (PRP) PLT concentrates prepared from whole blood. We hypothesized that 7-day-stored BC-PLTs would have superior autologous recoveries and survivals compared to PRP-PLTs and that both would meet the Food and Drug Administration (FDA) criteria for poststorage viability
- 2008 - 2011 Exploratory in vitro study of red blood cell storage container
BASF Corporation
Co-Investigator (PI: L. Dumont)
The BASF Corporation developed a new red blood cell storage container. Our laboratory analyzed the impact on this device on in vitro characteristics of erythrocytes.

- 2008 - 2012 Automated whole blood collection using the Tacura Separator system with in vitro and in vivo evaluation of prepared leukoreduced AS-5 RBCs and CPD plasma.
Terumo Corporation
Co-Investigator (PI: L. Dumont)
This study evaluated the impact of a new blood separator and RBC additive solution on in vitro and in vivo characteristics of erythrocytes. The red blood cell survival and recovery in combination with other in vitro factors were evaluated. The results of this study served as the scientific support for 510k application to FDA.
- 2008 - 2013 BCT08-10TrimaV.6pltRL: Trima Accl Version 6.0 for the Collection, Dilution and 5-day Storage of Hyperconcentrated Platelets in Isolyte@S pH 7.4
CaridianBCT (after 2011 Terumo BCT)
Co-Investigator (PI: L. Dumont)
This study focused on the impact of new version of cell separator on platelet product. The platelets were resuspended in higher concentration and in platelet additive solution. The work served to support 510k submission.
- 2008 - 2013 A randomized, single-blind, controlled, 2-period crossover study of recovery and lifespan of radiolabeled autologous 35-day-old red blood cells prepared with S-303
Cerus Corporation
Co-Investigator (PI: L. Dumont)
Pathogen inactivation methods rely on psoralen like molecules, in this study S-303. Their impact on RBC structure is being studied to move the product to larger clinical studies. In this study healthy subjects were transfused with red blood cells treated with S-303 and untreated and the impact of S-303 on recovery and survival as well as alloimmunization was studied.
- 2008 - 2013 Collaborative MS Research Center Award
National Multiple Sclerosis Society
Co-Investigator (PI: LH Kasper)
In this study the role of regulatory T cells on progression and clinical outcomes in multiple sclerosis were studied. The study envisioned preparation of autologous regulatory T cells in vitro with infusion in vivo to evaluate their impact.
- 2009 - 2012 Development and validation of cGMP process for the preparation, storage and distribution of cryopreserved platelets (CPP) for transfusion
Subcontract "Clinical Research Management" with the United States Army Medical Research Acquisition Activity (USMARA) Sponsor: The Department of the Army's Office of the Surgeon General (2009-2012)
Sub-Investigator 5% (PI: L. Dumont)
This study was continuation of previous work on cryopreserved platelets. The primary objective was to create the process to manufacture cryopreserved platelets in cGMP environment. The product were tested both in vitro and in vivo including healthy subjects.
- 2010 - 2012 Melanoma-specific T central memory cells for use in clinical trials.
Cancer Center Developmental Funds (Pilot Projects)
Co-Investigator (PI: M. Ernstoff)
This study was initiated to evaluate the use of T cells expanded in vitro as an adjuvant in treatment of patient with metastatic melanoma. This was a pilot study, which did not lead to clinical trial due to departure of the PI.

- 2010-2014 Comparison of different photopheresis instruments in generation of apoptosis in healthy subjects
Therakos, Inc
Co-Principal Investigator (Co-PI SH. Abhyankar)
The primary goal was to show that the apoptosis observed in the mononuclear cells after treatment with photoactivation and psoralen is independent of the cells being collected by apheresis. Two different devices were studied and analysis in vitro on the in vivo collected cell was performed.
- 2014 - 2017 Phase I dose escalation in frozen platelet transfusion in blood patients
Department of Defense
Site-PI, (PIs S Slichter, J Cancelas, L Dumont)
This is a multicenter phase I clinical study where cancer patients with grade I/II bleeding received cGMP manufactured (Dartmouth) cryopreserved platelets. The dose of platelets was escalated from half unit to 3 units in cohort design with single patient control. The study primary focus was safety, which was shown, though also some efficacy was appreciated as well.
- 2016 - 2017 Evaluation of amotasalen treated platelets
Cerus Inc
Site-PI
Goal of this study was to evaluate the impact on amotasalen on platelet function and survival in healthy subjects.
- 2017 - 2021 Phase I thrombosome use in bleeding patients.
Cellphire Inc, funding provided by BARDA
Site-PI
The primary goal of this study is to determine safety of thrombosomes (lyophilized platelets) in thrombocytopenic bleeding patients. The study design includes 4 cohorts and 4-6 study sites. The collected data will lead to pivotal study.
- 2015 – 2022 Evaluation of Plasma Exchange in ALS patients
Grifols, Inc
Co-Investigator (PI: E. Stommel)
The role of plasma exchange in treatment of ALS patients is being evaluated by long term (24 weeks) treatment with TPE. The patients are evaluated on progression of the disease but primarily on changes in biochemical markers during plasma exchange. The total study will have 10 evaluable patients.
- 2019 - 2023 MATX-004
Fresenius - Kabi
Site-PI
The primary objective of this sponsored study is to compare different types of plastic used for collection and storage of blood components. The evaluation involves comparison of basic characteristics of stored blood.
- 2019 2023 Cytosorbent
Site-PI

2021-2023 EryDel, Spa
 Site-PI

C. PENDING SUPPORT

XIV. PROGRAM DEVELOPMENT (List any educational, clinical or research entities at Dartmouth that were created or notably advanced by your efforts):

For internal use only.

XV. ENTREPRENEURIAL ACTIVITIES (List any patents, licenses or other entrepreneurial activities):

NONE

XVI. MAJOR COMMITTEE ASSIGNMENTS:**National/international**

<u>DATES</u>	<u>COMMITTEE</u>	<u>ROLE</u>	<u>INSTITUTION</u>
1999 – 2003	Cellular Therapy Committee	Vice-Chair	AABB
2001 – 2002	HPC Standards Program Unit	Chair	AABB
2001 – 2002	Circular of Information for HPC, Multi-organizational Committee	Co-Chair	AABB
2002 – 2007	Cellular Therapy Standards Program Unit	Chair	AABB
2003 – 2004	Board of Directors	Director	American Society for Apheresis
2004 – 2007	Clinical Applications and Standard Committee	Chair	American Society for Apheresis
2004 – 2007	Board of Directors	Treasurer	American Society for Apheresis
2004	SBIR Section ZRG1 HEME-B (10)	Ad-hoc Member	NIH
2004 – 2005	Cellular Therapy Team	Associate Scientific Member	BEST Collaborative
2004 – 2010	Standards Committee	Chair	National Marrow Donor Program
2005 – 2007	Circular of Information for Cellular Therapy Products, Multi-organizational Task Force	Chair	AABB
2005	SCCOR Review Group (Transfusion Medicine)	Member	NHLBI
2005 – 2006	Collection Standards Committee	Vice-Chair	FACT

2005 – 2018	Cellular Therapy Team and Member, Executive Committee	Co-Leader	BEST Collaborative
2006 – 2008	Northeast Representative, Nominating Committee	Member	AABB
2006 – 2010	Executive and Advisory Committee (equivalent to Board of Directors)	Nominated Member (representing collection sites)	CIBMTR
2007 – 2008	Board of Directors	Vice-President	American Society for Apheresis
2007 – 2009	Clinical Applications and Standard Committee	Vice-Chair	American Society for Apheresis
2007 – 2010	Circular of Information for Cellular Therapy Products, Multi-organizational International Task Force	Chair	AABB
2007 – present	SBIR Section ZRG1 HEMED (10)	Ad-hoc Member	NIH (17 review sessions)
2008 – 2009	Board of Directors	President-elect	American Society for Apheresis
2008 – 2009	Scientific Advisory Board	Member	Fenwal Inc.
2008 – 2009	30th Annual Meeting Organizing Committee	Chair	American Society for Apheresis
2009	Reviewer Special Emphasis Panel/Scientific Review Group 2009/10 ZHL1 CCT-I (C1/C2)	Production Assistance for Cellular Therapies	NHLBI
2009	State of the Science in Transfusion Medicine	Co-Chair of subcommittee	NHLBI
2009 – 2010	Board of Directors	President	American Society for Apheresis
2009 – 2018	Board of Directors	Director	AABB
2010 – 2011	Board of Directors	Immediate Past President	American Society for Apheresis
2010 – 2011	Nominating Committee	Chair	American Society for Apheresis
2010 – 2011	Past Presidents Advisory Council	Chair	American Society for Apheresis
2010 – 2020	New Technologies and Opportunities Advisory Group	Chair	National Marrow Donor Program
2010 – 2015	Board of Directors	Director	National Marrow Donor Program
2010 – present	Scientific Advisory Board	Member	Fenwal, Inc / Fresenius Kabi

2011 – 2013	Board of Directors Development Committee	Chair	National Marrow Donor Program
2011 – 2013	Executive Committee, Board of Directors	Treasurer (Chair of the Finance Committee)	AABB
2011 – 2014	Board of Trustees	Trustee	National Blood Foundation RET
2012 – 2013	International Committee	Vice-Chair	American Society for Apheresis
2012	State of the Science in Apheresis Medicine	Co-Chair	NHLBI
2012 – 2013	CEO Search Committee	Member	AABB
2012 – present	NHLBI Transfusion Medicine SEP [ZRG1 VH-F(50)S]	Member	NHLBI (5 sessions)
2013 – 2015	International Committee	Chair	American Society for Apheresis
2012 – 2013	Executive Committee, Board of Directors	Secretary	National Marrow Donor Program
2012 – 2014	Compensation Committee	Member	National Marrow Donor Program
2013 – 2014	Executive Committee, Board of Directors	Secretary	AABB
2013 – 2014	Audit and Ethics Committee	Chair	AABB
2014 – 2015	Executive Committee, Board of Directors	Vice-President	AABB
2014 – 2015	Human Resource Committee	Chair	AABB
2014 – 2016	Board of Directors	Treasurer	World Apheresis Association
2014 – present	Cellular Therapy Laboratory Advisory Group (CTCLAG)	Chair	ICCBBA
2014 – present	Standards Committee of ICCBBA	Member	ICCBBA
2014 – 2016	Finance Committee	Member	National Marrow Donor Program
2015 – present	ACBTSA Subcommittee on US Blood Sustainability	Member	US Department of Human and Health Services
2015- 2018	Ad hoc Task Force – Risk Based Decision Making – Babesiosis	Chair	AABB
2015- 2016	Governance Committee	Chair	AABB
2015 -2016	Executive Committee, Board of Directors	President-Elect	AABB
2015	Special Emphasis Panel/Scientific Review	Reviewer	NIH CSR

Group 2015/08 ZHL1 CSR-B
(S1) and (S3)

Regional

<u>DATES</u>	<u>COMMITTEE</u>	<u>ROLE</u>	<u>INSTITUTION</u>
2008 – present	Medical Advisory Committee	Member	American Red Cross Blood Services, New England Region

Institutional

<u>DATES</u>	<u>COMMITTEE</u>	<u>ROLE</u>	<u>INSTITUTION</u>
1998 – 2003	Transfusion Committee	Member	MGH, Boston, MA
1998 – 2003	Laboratory Medicine Clinical Advisory Committee	Member	MGH, Boston, MA
2000 – 2003	Internet Strategy Committee, Dept. of Pathology	Member	MGH, Boston, MA
2001 – 2003	Steering Committee, Dept. of Pathology, Division of Molecular Pathology and Research	Member	MGH, Boston, MA
2003 – 2004	Transfusion Committee	Member	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2003 – present	Allogeneic BMT Working Group	Member	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2004	Search Committee for Academic Hematopathologist, Dept. of Pathology	Chair	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2005	Search Committee for Director of Cell Labeling Laboratory, Dept. of Pathology	Chair	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2005 – present	Transfusion Committee	Chair	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2007 – 2008	Search Committee for Clinical Chemistry Director, Dept. of Pathology	Chair	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2007 – 2012	Trauma Improvement Quality Program	Member	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2008 – present	GME Advisory Committee	Member	Dartmouth-Hitchcock Medical Center, Lebanon, NH

2010 – 2013	Residency Program, Dept. of Pathology	Associate Director	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2012 – 2015	Faculty Council	Pathology representative	Geisel School of Medicine
2013 – 2015	Faculty Council – Finance Committee	Member	Geisel School of Medicine
2013- present	Residency Program, Dept of Pathology and Laboratory Medicine	Member	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2015 – present	Radiation Safety Committee	Member	Dartmouth-Hitchcock Medical Center, Lebanon, NH

XVII. MEMBERSHIPS, OFFICE AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

<u>DATES</u>	<u>SOCIETY</u>	<u>ROLE</u>
1989 - present	Royal Society of Medicine, London, UK	Fellow
1993 – present	American Association for the Advancement of Science (AAAS)	Member
1995 – present	AABB (formerly American Association of Blood Banks)	Member
1995 – present	College of American Pathologists (CAP)	Fellow (FCAP)
1995 – present	Massachusetts Medical Society (MMS)	Member
1996 – 2001	American Society of Clinical Pathologists (ASCP)	Fellow
1996 – present	American Society for Apheresis (ASFA)	Member
1997 – 1998	College of American Pathologists (CAP)	Resident Member, Transfusion Transmitted Viruses Resource Committee
1997 – 1999	Massachusetts Medical Society (MMS)	Member, Committee on International Medical Graduates
1998 – 1999	Massachusetts Medical Society (MMS)	Alternate Delegate, House of Delegates
1998 – 2002	American Society of Clinical Pathologists	National Contributor to ASCP Resident in Service Exam (RISE)
1999 – present	International Society for Cell Therapy (ISCT) (formerly International Society for Hemotherapy and Graft Engineering (ISHAGE))	Member

2000 – 2002	AABB	Liaison, Cord Blood Standard Committee, involved in writing the first edition of AABB standards for Cord Blood facilities
2000 – 2002	AABB	Liaison, Hematopoietic Progenitor Cell Standard Committee, involved in writing the third edition of AABB standards for HPC facilities
2000 – 2002	AABB	Liaison, Hematopoietic Progenitor Cell Accreditation Program, involved in writing the assessment tool for HPC and Cord Blood Banks
2000	American Society for Apheresis	Moderator, Abstract Sessions
2000 -2004	American Society for Apheresis	Member, Standards and Clinical Applications Committee
2000 – present	Foundation for the Accreditation of Cellular Therapy (FACT) [formerly Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT)]	Inspector for Collection and Processing Facilities (36 inspections as of 09/2022)
2001 – 2002	AABB	Member, Hemapheresis Committee
2001	AABB	Moderator, Facilitator, RAP session on cellular therapies, Annual Meeting, San Antonio, TX
2001 – present	AABB	Abstract Reviewer, Annual Meetings
2002	AABB	Moderator and Session Director – Somatic Cell Therapies, Annual Meeting 2002, Orlando, FL
2003	AABB	Moderator and Session Director – Regenerative Medicine, Annual Meeting 2003, San Diego, CA
2003	American Society for Apheresis	Scientific Session Chair – 24 th Annual Meeting, Lake Tahoe, CA
2003	Foundation for the Accreditation of Cellular Therapy	Member, Guidance Committee
2003 – 2007	AABB	Consultant, Cellular Therapies Committee
2003 – present	American Society of Hematology (ASH)	Member
2003 – present	National Marrow Donor Program (NMDP)	Director, Apheresis Center

2004	AABB	Liaison, NMDP Standards Committee
2004 – 2018	The Biomedical Excellence for Safer Transfusion (BEST) Collaborative	Member, Cellular Therapy Team
2004 – 2012	National Marrow Donor Program	Member, Standards Committee
2004 – present	American Society for Apheresis	Moderator, Abstract Sessions, Annual Meeting
2004 – present	International Society for Blood Transfusion (ISBT)	Member
2005 – 2018	The Biomedical Excellence for Safer Transfusion (BEST) Collaborative	Co-Leader CT Team and Executive Committee Member
2005 – 2008	Foundation for the Accreditation of Cellular Therapy	Standards Committee, Member
2005 – 2006	Foundation for the Accreditation of Cellular Therapy	Standards Committee, Collection Subcommittee, Vice-Chair
2005 – 2006	Foundation for the Accreditation of Cellular Therapy	Member, Standards Oversight Committee
2005 – 2006	Foundation for the Accreditation of Cellular Therapy	Vice-Chair, Collection Standards Committee
2005 – 2007	International Society for Cell Therapy	Member, NonHomologous Use Working Group (representing ASFA)
2005 – 2007	AABB	Member, Uniform Donor Questionnaire for HPC Donors
2005 – 2009	AABB	Member, Oversight Committee for Cellular Therapy
2005 – 2011	College of American Pathologists	Member, Transfusion Medicine Resource Committee
2005 – 2018	American Society for Apheresis	Member, Abstract Committee
2006	International Society for Cell Therapy	Member, Organizing Committee of Somatic Cell Meeting 2006
2006 – 2008	AABB	Member, Northeast Representative, Nominating Committee
2006 – 2009	American Society for Apheresis	Faculty, Clinical Rounds, Annual Meeting
2006 - 2010	Center for International Bone Marrow Transplant Research (CIBMTR)	Nominated Member (representing collection sites) Executive and Advisory Committee (equivalent to Board of Directors)
2006 – 2015	American Society for Apheresis	Member, Resident and Fellows Training Ad Hoc Committee
2006 – 2015	American Society for Apheresis	Liaison ISBT 128 Technical Advisory Group (ICCBBA)
2007	AABB	Moderator and Session Director – Cancer Vaccines and

2007 - 2008	American Society for Apheresis	Immunotherapy, Annual Meeting 2007, Anaheim, CA Vice-President, Board of Directors
2007 – 2008	Foundation for the Accreditation of Cellular Therapy	Standards Committee, Processing Subcommittee, Member
2007 – 2009	American Society for Apheresis	Vice-Chair, Clinical Applications and Standard Committee
2007 – 2009	AABB	Member, Cellular Therapy Committee
2007 – 2010	AABB	Chair, Circular of Information for Cellular Therapy Products, Multi-organization International Task Force
2007 – 2012	Foundation for the Accreditation of Cellular Therapy	Member, Professional Relations Committee
2008	AABB	Moderator, Session Director and Presenter – Interlaboratory Proficiency Testing in Cellular Therapy, Annual Meeting 2008, Montreal, QC
2008	AABB	Moderator and Presenter – Practice in Cellular Therapy Laboratory, Annual Meeting 2008, Montreal, QC
2008	American Society of Hematology	Reviewer, Abstract Committee
2008 – 2009	American Society for Apheresis	President-elect, Board of Directors
2008 – 2009	American Society for Apheresis	Chair, 30 th Annual Meeting Organizing Committee
2008 – 2014	College of American Pathologists	Member, FDA Liaison Committee (hosted by ISCT)
2008 – present	American Society for Apheresis	Member, Apheresis Applications Committee
2009	NHLBI	Co-Chair of Subcommittee, State of the Science in Transfusion Medicine
2009	AABB	Moderator; Presenter – RAP Session on infusion of CT Products; Annual Meeting 2009, New Orleans, LA
2009	AABB	Moderator – “Speed Dating” on Cellular Therapy Topics; Annual Meeting 2009, New Orleans, LA
2009 – 2010	American Society for Apheresis	President, Board of Directors
2009 – 2018	AABB	Director, Board of Directors

2009 – present	International Society for Blood Transfusion	Member, Infectious Disease Working Group; Bacteria Group
2009 – 2018	International Society for Blood Transfusion	Member, Apheresis Working Group (discontinued in 2018)
2010 – 2011	American Society for Apheresis	Immediate Past President, Board of Directors
2010 – 2011	American Society for Apheresis	Chair, Nominating Committee
2010 – 2011	American Society for Apheresis	Chair, Past Presidents Advisory Council
2010 – 2012	College of American Pathologists	Member, Module 2, Transformation Team
2010 – 2012	American Society for Apheresis	Member, International Affairs Committee
2010 – 2012	American Society for Apheresis	Liaison to World Apheresis Association (WAA); Councilor
2010 – 2020	National Marrow Donor Program	Chair, New Technologies and Opportunities Advisory Group
2011 – 2013	AABB	Treasurer (Chair the Finance Committee), Executive Committee, Board of Directors
2011 – 2015	National Marrow Donor Program	Member, Board of Directors Development Committee
2011 – 2013	National Marrow Donor Program	Chair, Board of Directors Development Committee
2011 – present	ICCBBA, Inc.	Member, Cellular Therapy Laboratory Advisory Group
2011 – present	International Collaboration for the Development, Implementation, Evaluation of Guidelines for Transfusion Therapies (ICTMG)	Member (elected)
2012	American Society of Hematology	Reviewer, Abstract Committee/Education Book
2012	NHLBI	Co-Chair, State of the Science in Apheresis Medicine
2012 – 2013	American Society for Apheresis	Vice-Chair, International Committee
2012 – 2013	AABB	Member, CEO Search Committee
2012 – 2013	National Marrow Donor Program	Secretary, Executive Committee, Board of Directors
2012 – 2014	National Marrow Donor Program	Member, Compensation Committee
2013 – 2014	AABB	Secretary, Executive Committee, Board of Directors
2013 – 2014	AABB	Chair, Audit and Ethics Committee
2013 – 2015	American Society for Apheresis	Chair, International Committee

2013 – present	International Society for Blood Transfusion	Member, Cellular Therapy Working Group
2014 – 2015	AABB	Vice-President, Executive Committee, Board of Directors
2014 – 2015	AABB	Chair, Human Resource Committee
2014 – 2016	National Marrow Donor Program	Member, Finance Committee
2014 – 2023	ICCBBA, Inc.	Chair, Cellular Therapy Laboratory Advisory Group
2014 – present	ICCBBA, Inc.	Member, Standards Committee
2015 – 2016	AABB	Chair, Governance Committee
2015 – 2016	AABB	President-Elect, Executive Committee, Board of Directors
2015 – 2017	AABB	Chair, Ad hoc Task Force – Risk Based Decision Making – Babesiosis
2015 – present	International Collaboration for the Development, Implementation, Evaluation of Guidelines for Transfusion Therapies (ICTMG)	Member, Dissemination Committee
2015 – present	American Society for Apheresis	Member, International Committee
2015 – 2022	US Department of Human and Health Services	Member, ACBTSA Subcommittee on US Blood Sustainability
2016 – 2017	AABB	President, Executive Committee, Board of Directors
2017 – 2018	AABB	Chair, CEO Search Committee
2017 – present	Polish Society of Haematology and Transfusion Medicine (PTHIT)	Member
2017 – 2019	AABB	Member, Guidance Harmonization Working Group (AABB representative)
2017 – 2018	AABB	Immediate Past President, Executive Committee, Board of Directors
2017 – 2018	The Biomedical Excellence for Safer Transfusion (BEST) Collaborative	Chair-Elect
2018 – 2022	The Biomedical Excellence for Safer Transfusion (BEST) Collaborative	President/Chair, Executive Committee
2018	American Society of Hematology	Moderator, Transfusion Medicine Educational Session
2018 – 2019	AABB	Chair, Nominating Committee
2018 – present	College of American Pathologists	Member, Transfusion, Apheresis and Cellular Therapy Committee (TACT) (previously Transfusion Medicine Resource Committee)

2018 – present	International Collaboration for the Development, Implementation, Evaluation of Guidelines for Transfusion Therapies (ICTMG)	Co-Chair, Editorial Committee Member, Executive Committee
2022 – present	The Biomedical Excellence for Safer Transfusion (BEST) Collaborative	Treasurer, Board of Directors Interim President (2023)

XVIII. EDITORIAL BOARDS:

<u>DATES</u>	<u>SOCIETY</u>	<u>ROLE</u>
2004 – present	Journal of Clinical Apheresis	Associate Editor
2008 – present	Journal of Transfusion Medicine (Warsaw)	Member
2008 – present	Journal of Translational Medicine (Cellular Therapy)	Member
2011 – present	Vox Sanguinis	Editor (Reviews)
2011 – present	Acta Hematologica Polonica	Member
2012 – present	Drugs and Cell Therapies in Hematology	Section Editor
2014 – present	Vox Sanguinis	Editor (Cell Therapy)
2014 – present	Faculty 1000	Section Editor, Hematology
2020 – present	Plasmatology	Associate Editor

XIX. JOURNAL REFEREE ACTIVITY:

<u>DATES</u>	<u>JOURNAL NAME</u>	<u>ANNUAL FREQUENCY OF REVIEW</u>
	Archives of Internal Medicine (JAMA group)	
	Blood	
	Bone Marrow Transplantation (Nature group)	
	Cytotherapy	
	Journal of American Medical Association (JAMA)	
	Journal of Clinical Apheresis	
	Polish Archives of Internal Medicine	
	Transfusion	
	Transfusion Medicine	
	Transfusion Medicine Reviews	
	Vox Sanguinis	
Non journal	Harvard / Center for Integration of Medicine and Innovative Technology	
Non journal	NHLBI SMARTT Reviewer	

XX. AWARDS AND HONORS:

<u>DATES</u>	<u>AWARD NAME</u>
1984	Ranked 2 nd in a class of 100, St. Augustine’s Lyceum, Warsaw, Poland
1985 – 1986	Prizes of the Rector of Medical Academy in Warsaw, Poland
1988 – 1989	Prizes of the Rector of Medical Academy in Warsaw, Poland

- 1989 1st Prize of the National Meeting of Student Scientific Societies, Katowice, Poland
- 1989 – 1990 Mayoral Scholarship, Warsaw, Poland
- 1990 1st Prize of the National Meeting of Student Scientific Societies, Katowice, Poland
- 1991 Ranked 3rd in a class of 156, Warsaw Medical University, Warsaw, Poland
- 1993 The Dr. Charles Trey Postdoctoral Research Fellowship Award, American Liver Foundation, USA
- 2001 Partners in Excellence Award (Outstanding Performance and Commitment to Excellence)
- 2003 Clinical Pathology Teacher of the Year, Massachusetts General Hospital, Boston, MA
- 2005 Award for Logo Design of American Society for Apheresis
- 2012 Presidential Award, American Society for Apheresis
- 2015 Society Medal, Polish Society of Hematology and Transfusion (PTHiT)
- 2019 Emil-von-Behring Lecture Award; German Society of Transfusion Medicine and Immunohematology (DGTI)
- 2020 Francis S. Morrison Lecture Award; American Association for Apheresis

XXI. INVITED PRESENTATIONS:**A. International:**

<u>DATE</u>	<u>TOPIC/TITLE</u>	<u>ORGANIZATION</u>	<u>LOCATION</u>
2001	State of the Art in HPCs: An Overview – Cord Blood Transplantation	AABB/ISHAGE Audioconference	
2002	Sources of Hematopoietic Progenitor Cells and Their Use in the US. AABB Standards for HP Services, 3 rd edition Audioconference		
2002	Sources of Hematopoietic Progenitor Cells and Their Use in the US. II Macopharma Symposium, Poznan, Poland (sponsored by Macopharma, Lyon, FR)		
2004	Variables in Dendritic Cell Preparation. BEST Collaborative, Bermuda		
2004	Bacterial Contamination of Platelets - US perspective. IV Macopharma Symposium, Poznan, Poland (sponsored by Macopharma, Lyon, FR)		
2004	Platelets and pathogen inactivation. IV Macopharma Symposium, Poznan, Poland (sponsored by Macopharma, Lyon, FR)		
2005	AABB Standards for Cellular Therapy Products, 1st Ed. AABB Audioconference		
2005	Ask the Regulatory Experts. ISCT Annual Meeting, Vancouver, BC		
2005	Leukoreduction of blood components in the US – an update. V Macopharma Symposium, Zakrzewo, Poland (sponsored by Macopharma, Lyon, FR)		
2008	Standards in Cellular Therapy. Sírio Libanês Hospital, Sao Paulo, Brazil		
2008	HLA in Cellular Therapy. Sírio Libanês Hospital, Sao Paulo, Brazil		
2009	Evidence Based Therapeutic Apheresis. British Society of Hematology, Brighton, UK		
2010	Different types of TTP. XIII World Apheresis Association Meeting, Interlaken, Switzerland		
2010	New Therapeutic Apheresis Guidelines. XIII World Apheresis Association Meeting, Interlaken, Switzerland		
2011	Guidelines in Therapeutic Apheresis. XXIV Annual Meeting, Polish Society of Hematology and Transfusion, Lublin, Poland		

- 2011 New Treatment Modalities in Therapeutic Apheresis and ASFA Guidelines.XV Congress of SldEM, Torino, Italy
- 2012 Evidence Based Medicine. Interdisciplinary European Society for Haemapheresis and Haemotherapy (ESFH), The Hague, Netherlands
- 2012 Cellular Therapy at the Tertiary Care Hospital in the United States. The past, the present, and the future. 4th Bad Homburg Forum, Fresenius SA, Bad Homburg, Germany. Sponsored by Fresenius SA
- 2012 The BEST Collaborative in Cellular Therapy: Achievements, Challenges and Future Directions. XIV World Apheresis Congress, Istanbul, Turkey
- 2013 Cryopreservation and cellular function. ISCT Annual Meeting, Auckland, New Zealand
- 2013 National Marrow Donor Program - its role in HSCT. XXV Annual Meeting, Polish Society of Hematology and Transfusion, Poznan, Poland
- 2014 Apheresis Medicine – the art of evidence based clinical practice. 2nd International Joint Meeting ESFH-SIDEM, Florence, Italy
- 2014 THERAPEUTIC APHERESIS: The Principles, the Evidence and the Future. IX Biennial Conference Barcelona-Pittsburgh, Barcelona, Spain. Sponsored by Grifols, Inc.
- 2014 Platelet transfusions: intersection of clinical practice and evidence based guidelines. Annual Meeting of DGTI, Dresden, Germany
- 2015 Cryopreservation and T cell function. Pre BEST educational session, Lille, France
- 2015 Current challenges in securing safe blood in the US – critical update in the risk based decision making. XXVI Annual Meeting, Polish Society of Hematology and Transfusion, Szczecin, Poland
- 2016 Transfusion Medicine in the United States: Introduction, AABB, and Clinical Guidelines. Committee on Quality; Chine Transfusion Society, Yinchuan, China Sponsored by Fresenius Kabi, China
- 2016 Transfusion Medicine in the United States: Current Situation and New Developments. Committee on Quality; Chine Transfusion Society, Yinchuan, China. Sponsored by Fresenius Kabi, China
- 2016 Transfusion Medicine in the United States: Introduction, AABB, and Clinical Guidelines. FK Transfusion Annual Seminar, Chengdu, China. Sponsored by Fresenius Kabi, China

- 2016 Transfusion Medicine in the United States: Current Situation and New Developments. FK Transfusion Annual Seminar, Chengdu, China. Sponsored by Fresenius Kabi, China
- 2016 Therapeutic Apheresis – New Indications Status 2016. 2nd Symposium Research – Education, Warsaw, Poland. Sponsored by Terumo BCT, Europe
- 2017 Transfusion Medicine – Quality, Value and Risk. MedLab Meeting, Dubai, UAE
- 2017 Current Trends in Platelet: Collection, Testing and Storage. FACT 2017 Meeting, Seoul, Korea. Sponsored by Fresenius Kabi, Asia
- 2017 Bacterial Contamination of Platelets – Different Pathways in the US. XXVII Annual Meeting, Polish Society of Hematology and Transfusion, Warsaw, Poland
- 2017 Transfusion of Blood Components in the Era of Evidence Based Medicine. XXVII Annual Meeting, Polish Society of Hematology and Transfusion, Warsaw, Poland
- 2017 Transfusion Medicine in the United States – 2017. Meeting of Transfusion Medicine Section of PTHIT, Warsaw, Poland
- 2017 Transfusion of Blood Components in the Era of Evidence Based Medicine. Annual Meeting; National Center for Transfusion, Vilnius, Lithuania (video link)
- 2018 Thrombotic Thrombocytopenic Purpura – a 360-degree approach. Annual AABB Highlights in Middle East, Abu Dhabi, UAE
- 2019 Transfusion Medicine/Apheresis; Highlights of ASH Annual Meeting in South-East Asia; Bangkok, Thailand
- 2019 The Future of Transfusion Medicine; PTHiT Meeting, Lodz, Poland
Extracorporeal Photopheresis; PTHiT Meeting, Lodz, Poland
- 2019 Transfusion Medicine the Multifaceted Clinical Specialty (Emil-von-Behring Lecture); DGTI Meeting; Mannheim, Germany;

B. National:

<u>DATE</u>	<u>TOPIC/TITLE</u>	<u>ORGANIZATION</u>	<u>LOCATION</u>
2001	Update on Applications of PBSC for Breast and Ovarian Cancer.	ASFA Annual Meeting (filling in for Iain Webb MD),	Niagara Falls, NY
2001	Cord Blood Transplantation / Lecture. (CME),	AABB/ISHAGE Audioconference	
2002	3 rd edition HPC Standards / Lecture. (CME),	AABB Audioconference	

- 2003 The role of apheresis in renal transplantation. Scientific Session, XXIV Annual ASFA Meeting, Lake Tahoe, CA
- 2003 Ask the Standards Committee. AABB, San Diego, CA
- 2003 Therapeutic Apheresis in renal transplantation. (CME) AABB, San Diego, CA
- 2003 Dendritic Cell Immunotherapy. (CME) AABB, San Diego, CA
- 2004 Donor Safety / Panelist. NIH sponsored conference, Arlington, MD
- 2004 Ask the Standards Committee. AABB, Baltimore, MD
- 2004 Dendritic Cell Immunotherapy. (CME) AABB, Baltimore, MD
- 2005 1st edition Cellular Therapy Standards / Lecture. (CME) AABB Audioconference
- 2005 Challenging HPC Donor. (CME) ASFA Annual Meeting, Chicago, IL
- 2005 Transfusion Medicine and Cellular Therapy: At the Crossroads. (CME) CAP Annual Meeting, Chicago, IL
- 2005 Ask the Standards Committee. AABB, Seattle, WA
- 2005 Standards in Cord Blood Banking. (CME) AABB, Seattle, WA
- 2006 Ask the Standards Committee. AABB, Miami, FL
- 2007 Cellular Immunotherapy – Dendritic Cells. (CME) AABB Spring Conf., San Diego, CA
- 2007 The new approach to ASFA Indications for Therapeutic Apheresis. (CME) Opening Symposium, ASFA Annual Meeting, Nashville, TN
- 2007 The new approach to ASFA Indications for Therapeutic Apheresis. (CME) AABB Annual Meeting, Anaheim, CA
- 2007 2nd edition of Cellular Therapy Standards / Lecture. (CME) AABB Audioconference
- 2007 ASFA/Cellular Therapy Topics / Lecture. (CME) AABB Audioconference
- 2007 Stem Cell Collections – The Newest Blood Bank Component / Lecture. (CME) ASCP Audioconference

- 2008 Assignment of ASFA Interim Categories. (CME) AABB Annual Meeting, Montreal, QC
- 2008 Interactive Session on Cellular Therapy. AABB Annual Meeting, Montreal, QC
- 2008 Interlaboratory Proficiency Testing in Cellular Therapy. (CME) AABB Annual Meeting, Montreal, QC
- 2008 Dendritic Cells in Clinical Trials. (CME) Roswell Park Cancer Institute, Buffalo, NY
- 2009 BEST Collaborative and Cellular Therapy / Lecture. (CME) AABB Audioconference
- 2009 Implementation of ISBT 128 in a cellular therapy laboratory. (CME) ISCT Annual Meeting, San Diego, CA
- 2009 Transportation of cellular therapy products, BEST Collaborative. (CME) ISCT Annual Meeting, San Diego, CA
- 2009 The Effect of Mobilization and Collection Technique on HPC-A Product Composition. (CME) ISCT/AABB Joint Program, Annual Meeting, New Orleans, LA
- 2010 New Apheresis Guidelines / Lecture. (CME) ASFA Audioconference
- 2010 ASFA Categories, 2010 Special Issue. (CME) ASFA Annual Meeting, New Orleans, LA
- 2010 State of the Science Symposium – Update. (CME) ASFA Annual Meeting, New Orleans, LA
- 2010 BEST in the Future. (CME) AABB Annual Meeting, Baltimore, MD
- 2010 ASFA Categories 2010 Special Issue. (CME) AABB Annual Meeting, Baltimore, MD
- 2013 2012 NHLBI Symposium State of the Science in Therapeutic Apheresis – the roadmap for the future is here... (CME) ASFA Meeting, Denver, CO
- 2013 The BEST Collaborative Cellular Therapy Team. (CME) AABB Meeting, Denver, CO
- 2013 Short term pain and long term benefits – the rationale for changes to ISBT128 for CT products. (CME) AABB Meeting, Denver, CO

- 2013 Transfusion Guidelines: When to Transfuse... (CME) ASH Meeting, New Orleans, LA
- 2014 2012 NHLBI Symposium State of the Science in Therapeutic Apheresis – the roadmap is here...Are you ready...? (CME) ASFA Meeting, San Francisco, CA
- 2014 Challenging Situations in Transfusion Medicine: Indications for Red Cell, Platelet, and Fresh Frozen Plasma Transfusion. (CME) ASCO Meeting, Chicago, IL
- 2015 Safer platelets – the alternative approaches. (CME) Symposium on Pathogen Inactivation (AABB), Bethesda, MD
- 2015 Considerations for introduction of new blood safety and quality measures in the hospital setting. 47th Meeting of ACBTSA; HHS Committee, Washington, DC
- 2017 Future international collaboration in development of sustainable global blood system: 2017 perspective... / Keynote (CME) The International Blood Safety Forum 2017, Washington, DC
- 2017 Bacterial Contamination of Platelets the context of Risk Based Decision Making (RBDM). (CME) Annual Meeting of America’s Blood Centers, Washington, DC
- 2017 The Role of Professional Organizations in Cellular Therapy. (CME) CTACC – Cellular Therapeutics in Trauma and Critical Care, San Francisco, CA
- 2017 Red Cell Genetics and Patient Safety: What Resources are Available and What is Needed... / Keynote (CME) NIH Conference: Red Cell Genotyping 2017: Patient Safety, Bethesda, MD
- 2018 The Future of Stem Cell Therapies, What Every Transfusion Medicine Specialist Needs to Know / Keynote (CME) Blood Bank Association of New York State Annual Meeting, New York City, NY
- 2018 Blood Safety – presentation for AABB, ABC, and ARC – common statement 49th Meeting ACBTSA; HHS Committee, Washington, DC
- 2019 Transfusion Medicine – 2 presentations at Highlights of ASH Annual Meeting in the US – San Francisco, CA and Seattle, WA
- 2019 AMBAR – preliminary results of the phase IIb/III study of apheresis in Alzheimer’s Disease. 40th Annual ASFA Meeting; Portland, OR
- 2019 Universal Irradiation – Pros and Cons; AABB Webinar,
- 2019 AMBAR – Preliminary Results; Alzheimer's Association International Conference (AAIC), Los Angeles, CA

C. Regional/Institutional:

<u>DATE</u>	<u>TOPIC/TITLE</u>	<u>ORGANIZATION</u>	<u>LOCATION</u>
1998	Transfusion Medicine – Preoperative testing.	MGH Anesthesiology Ground Rounds, Boston, MA	
1998	Acute Hemolytic Transfusion Reactions.	MGH Mortality and Morbidity Conference, Boston, MA	
1998	TTP in HIV positive patients.	MGH Medicine Resident’s Report, Boston, MA	
1998-1999	Course in Cellular Pathology, Red Blood Cell Pathology and White Blood Cell. Pathology / Lecturer,	Northeastern University, Boston, MA	
1998	Microbiology, Retroviruses / Lecturer,	Northeastern University, Boston, MA	
1998	Narrative interpretations in Transfusion Medicine – the MGH experience.	33rd Annual ACLPS Meeting, Boston, MA	
1998	HELLP Syndrome.	Eastern Massachusetts Apheresis Group, Boston, MA	
1998	Diagnostic Testing in Hemostasis.	Mayo Medical Laboratories, Medical Staff Grand Round, Brunswick, ME	
1999	Hemolytic Disease of the Newborn.	Pediatric Chief’s Rounds, MGH/North Shore Hospital, Boston, MA	
1999	Transfusion Reactions.	Pediatric Chief’s Rounds, MGH/North Shore Hospital, Boston, MA	
1999	Autoimmune Hemolytic Anemia.	MGH Medicine Resident’s Report, Boston, MA	
1999	Use of RBC in surgical setting for house officers.	MGH Surgery, Boston, MA	
2000	Transfusion Medicine Cases. (2)	MGH Medicine Resident’s Report, Boston, MA	
2000	Therapeutic Apheresis – Introduction.	Harvard Hospitals Joint Transfusion Medicine Lecture Series, Boston, MA	
2000	Transfusion Medicine.	MGH Medicine Noon Conference, Boston, MA	
2000	Stem cells – is this the final answer.	Dartmouth-Hitchcock Medical Center, Lebanon, NH	
2000	Therapeutic apheresis – A primer.	Children’s Hospital, Boston, MA	

- 2000 Stem cells – is this the final answer. Massachusetts Associations of Blood Banks, Westford, MA
- 2001 Medical Bacteriology, Transfusion transmitted bacterial infections. Lecturer, Northeastern University, Boston, MA
- 2001 Mobilization and Collection of Hematopoietic Stem/Progenitor Cells. Pathology Grand Rounds, MGH, Boston, MA
- 2001 Transfusion Medicine. MGH Medicine Noon Conference, Boston, MA
- 2002 Standards and Federal Regulations in Somatic Cell Therapy. ARC New England Region, Dedham, MA
- 2003 Introduction to Cellular Therapies. Massachusetts Association of Blood Banks, Westford, MA
- 2003 Transfusion Medicine – Adverse Reactions. (2) MGH Medicine Noon Conference, Boston, MA
- 2003 BMT Technically Speaking. (4) Tech Lecture Series, MGH, Boston, MA
- 2004 Adoptive Immunotherapy. Massachusetts Association of Blood Banks, Westford, MA
- 2005 Transfusion Medicine and Cellular Therapy – Infatuation or long-term relationship. Rhode Island Blood Bank Society, Providence, RI
- 2005 Cellular Therapy for Technologists. (35) Mass General Hospital, Boston, MA
- 2005 Cellular Therapy in Your Backyard. Dartmouth Pathology Program, DHMC, Lebanon, NH
- 2007 Vascular Surgery and Transfusion Medicine. Vascular Surgery Scientific Meeting, DHMC, Lebanon, NH
- 2007 The new approach to ASFA Indications of Therapeutic Apheresis. ARC Advisory Committee, Dedham, MA
- 2008 Cellular Therapy Products in Cancer Immunotherapy. 60th Annual Meeting of the American Society of Clinical Laboratory Science, Central New England, Providence, RI
- 2008 Therapeutic Apheresis in Nephrology. Nephrology Section Meeting, DHMC, Lebanon, NH

- 2009 Evidence Based Therapeutic Apheresis. American Red Cross Seminar, West Lebanon, NH
- 2009 Therapeutic Apheresis in Rheumatology. Rheumatology Grand Rounds, DHMC, Lebanon, NH
- 2009 Blood Safety in the US. Special Meeting for delegation from Kyrgyzstan, DHMC, Lebanon, NH
- 2010 Cell Based Immunotherapy in Cancer – Dartmouth Experience. Massachusetts Association of Blood Banks, Westford, MA
- 2010 Therapeutic Apheresis – New Guidelines. American Red Cross Seminar, Worcester, MA
- 2015 Galen’s Humoralism of the XXIst century: Apheresis – Technology of the Future? Harvard Transfusion Medicine Grand Rounds, Boston, MA
- 2016 New developments in transfusion medicine – application to vascular surgery. Vascular Surgery Scientific Meeting, DHMC, Lebanon, NH
- 2016 Therapeutic Apheresis in Rheumatology. Rheumatology Grand Rounds, Lebanon, NH
- 2018 Transfusion Medicine 2018 and beyond – Pathology Department Grand Rounds, Mass General Hospital, Boston, MA

XXII. BIBLIOGRAPHY:**A. Peer-reviewed publications in print or other media****Original articles:**

1. Ostrowski J, Szczepiorkowski ZM, Trzeciak L, Rochowska M, Skurzak H, Butruk E. Induction of ornithine decarboxylase in normal and protein kinase C--depleted human colon carcinoma cells. *J Physiol Pharmacol* 1992; 43(4):373-82 (PMID: 1294268)
2. Szczepiorkowski ZM, Dickersin GR, Laposata M. Fatty acid ethyl esters decrease human hepatoblastoma cell proliferation and protein synthesis. *Gastroenterology* 1995; 108(2):515-525 and editorial by A.A. Spector pages 605-607 (PMID: 7835594)
3. Teruya J, Cluette-Brown J, Szczepiorkowski ZM, Laposata M. Mode of transport of fatty acid to endothelial cells influences intracellular fatty acid metabolism. *J Lipid Res* 1995; 36(2):266-276 (PMID: 7751814)
4. Bird DA, Szczepiorkowski ZM, Trace VC, Laposata M. Low-density lipoprotein reconstituted with fatty acid ethyl esters as a physiological vehicle for ethyl ester delivery to intact cells. *Alcohol Clin Exp Res* 1995; 19(5):1265-1270 (PMID: 8561300)
5. Hallaq J, Szczepiorkowski ZM, Teruya J, Cluette-Brown JE, Laposata M. Stability of plasma nonesterified arachidonate in healthy individuals in fasting and nonfasting states. *Clin Chem* 1996; 42(5):771-773 (PMID: 8653907)
6. Kabakibi A, Vamvakas EC, Cannistraro PA, Szczepiorkowski ZM, Laposata M. Collagen-induced whole blood platelet aggregation in patients undergoing surgical procedures associated with minimal to moderate blood loss. *Am J Clin Pathol* 1998; 109(4):392-398 (PMID: 9535391)
7. Palmer-Toy DE, Szczepiorkowski ZM, Shih V; Van Cott EM. Compatibility of the Abbott IMx homocysteine assay with citrate-anticoagulated plasma and stability of homocysteine in citrated whole blood. *Clin Chem* 2001; 47(9):1704-1707 (PMID: 11514408)
8. Kratz A, Soderberg BL, Szczepiorkowski ZM, Dighe AS, Versalovic J, Laposata M. The generation of narrative interpretations in laboratory medicine. A description of service-specific sign-out rounds. *Am J Clin Pathol* 2001; 116(Suppl):S133-S140 (PMID: 11993699)
9. Dellon ES, Szczepiorkowski ZM, Dzik WH, Graeme-Cook F, Ades A, Bloomer JR, Cosimi AB, Chung RT. Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. *Transplantation* 2002; 73(6):911-5 (PMID: 11923691)
10. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski ZM, Toner S, Cohen DE, Sax PE, Ukomadu C. Isolated antibody to

hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36(12):1602-5 (PMID: 12802762)

11. Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM, Casson DR, Chung RT, Bell S, Harcourt G, Walker BD, Klenerman P, Wucherpfennig KW. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112(6):831-42 (PMID: 12975468) (PMCID: PMC193667)
12. Eichbaum QG, Dzik WH, Chung RT, Szczepiorkowski ZM. Red blood cell exchange transfusion in two patients with advanced erythropoietic protoporphyria. Transfusion 2005; 45(2):208-213. (PMID: 15660829)
13. Agrawal YP, Freedman M, Szczepiorkowski ZM. Long-term transfusion of polymerized bovine hemoglobin to a Jehovah's witness following chemotherapy for myeloid leukemia: a case report. Transfusion 2005; 45(11):1735-8. Also Cover Illustration of this issue. (PMID: 16271098)
14. Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CM, Pollak MR, Brown EM, Scadden DT. Stem Cell Engraftment at the Endosteal Niche is Specified by the Calcium-Sensing Receptor. Nature 2006 Feb 2; 439(7076):599-603. (PMID: 16382241)
15. Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P, Szczepiorkowski ZM. Implementation of Peripheral Blood CD34 Analyses to Initiate Leukapheresis: Marked Reduction in Resource Utilization. Transfusion 2006; 46(4):523-9. (PMID: 16584427)
16. Best CA, Laposata M, Proios VG, Szczepiorkowski ZM. Method to assess fatty acid ethyl ester binding to albumin. Alcohol Alcohol 2006 May-June; 41(3):240-6. (PMID: 16554377)
17. Szczepiorkowski ZM, AuBuchon JP. The Role of Physicians in Hospital Transfusion Services. Transfusion 2006; 46(5):862-867. Cover Illustrations of this issue. (PMID: 16686856)
18. Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res 2007 Jan 15; 13(2 Pt 2):733s-740s (PMID: 17255302)
19. Pearson H, Davis KG, Wood EM, Coghlan PJ, Leitner GC, Hocker P, Panzer S, Mayr WR, Devine DV, Hume H, Howe D, Turek P, Chabanel A, Lee K, Bardiaux L, Proust F, Waller C, Francois A, Mercadier A, Cazenave JP, Andreu G, Politis C, Katsea P, Richardson C, Stavropoulou-Gioka A, Lin CK, Ohto H, Miyata S, Satake M, Vrieling H, Pietersz RN, Ghosh S, Scott R, Brojer E, Letowska M, Zupanska B, Zhiburt E, Lozano M, Mazzara R, Cid

- J, Norda R, Knutson F, Maclennan S, Gesinde M, Szczepiorkowski ZM, Aubuchon JP, Mantha S, Eisenbarth S, Champion M, Snyder E. Logistics of platelet concentrates. *Vox Sang*. 2007 Feb; 92(2):160-81.
20. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL. Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. *J Clin Apher* 2007 Jun; 22(3):106-75. (PMID: 17394188)
 21. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-Introduction to the fourth special issue: Clinical applications of therapeutic apheresis. *J Clin Apher* 2007 Jun; 22(3):96-105. (PMID: 17394186)
 22. Shaz BH, Linenberger ML, Bandarenko N, Winters JL, Kim HC, Marques MB, Sarode R, Schwartz J, Weinstein R, Wirk A, Szczepiorkowski ZM. Category IV indications for therapeutic apheresis: ASFA fourth special issue. *J Clin Apher* 2007 Jun; 22(3):176-80. (PMID: 17377982)
 23. Meehan KR, Wu J, Bengtson E, Hill J, Ely P, Szczepiorkowski Z, Kendall M, Ernstoff MS. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. *Bone Marrow Transplant* 2007; 39(11):695-703. (PMID: 17417660)
 24. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Standards for the terminology and labeling of cellular therapy products. *Transfusion* 2007 Jul; 47(7):1319-27. (PMID: 17581170)
J Clin Apher 2007; 22(5):249-57. (PMID: 17823945)
 25. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. ISBT 128 implementation plan for cellular therapy products. *Transfusion*. 2007 Jul; 47(7):1312-8 (PMID: 17581169)
J Clin Apher. 2007; 22(5):258-64 (PMID: 17823946)
 26. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Terminology and labeling of cellular products: 1. Standards. *Bone Marrow Transplant* 2007 Dec; 40(11):1075-83. (PMID: 17906708)
 27. Ashford P, Distler P, Gee A, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Terminology and

- labeling of cellular products-2: Implementation plan. Bone Marrow Transplant. 2007 Dec; 40(11):1085-90. (PMID: 17906707)
28. Shaz BH, Winters JL, Bandarenko N, Szczepiorkowski ZM. How we approach an apheresis request for a Category III, Category IV, or noncategorized indication. Transfusion 2007 Nov; 47(11):1963-1971. (PMID: 17958524)
 29. Meehan KR, Wu J, Webber SM, Barber A, Szczepiorkowski ZM, Sentman C. Development of a clinical model for ex-vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy 2008; 10(1):30-7. (PMID: 18202972)
 30. Eichler H, Nguyen XD, Roelen D, Celluzzi CM, McKenna D, Pamphilon D, Blair A, Read EJ, Takahashi TA, Szczepiorkowski ZM. Biomedical Excellence for Safer Transfusion Collaborative. Multicenter study on in vitro characterization of dendritic cells. Cytotherapy 2008; 10(1):21-9. (PMID: 18202971)
 31. Brand A, Eichler H, Szczepiorkowski ZM, Hess JR, Kekomaki R, McKenna DH, Pamphilon D, Reems J, Sacher RA, Takahashi TA, van de Watering LM. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise. Transfusion 2008; 48(3):546-9. (PMID: 18067495)
 32. AuBuchon JP, de Wildt-Eggen J, Dumont LJ. Biomedical Excellence for Safer Transfusion Collaborative; Transfusion Medicine Resource Committee of the College of American Pathologists. (Listed contributor) Vox Sang. 2008 Jul; 95(1):57-65. (PMID: 18479347)
 33. Dzik WS, Beckman N, Selleng K, Heddle N, Szczepiorkowski Z, Wendel S, Murphy M. Error in patient specimen collection: application of statistical process control. Transfusion 2008 Oct; 48(10):2143-51. (PMID: 18673352)
 34. Greene MR, Szczepiorkowski ZM, Meehan KR. Non-Myeloablative Peripheral Blood Stem Cell Transplant in a Patient With Platelet (HPA) Mismatch and Pre-Existing Anti-Donor Platelet Alloantibodies. American Journal of Hematology 2008; 7(3): 68-70
 35. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA. StoP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (StoP) to patients with thrombocytopenia. Blood 2009 Feb 12; 113(7):1564-73. (PMID: 19109560)
 36. Hardman RL, Forauer AR, Boykin RD, Szczepiorkowski ZM, Hill JM. Uterine artery embolization for menorrhagia. J Support Oncol. 2009 Jan-Feb; 7(1):47-50. (PMID: 19278179)
 37. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR,

- Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ, Ernstoff MS. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN- α 2a therapy in metastatic renal cell carcinoma patients. *Clin Cancer Res* 2009 Aug 1; 15(15):4986-92. (PMID: 19622576) (PMCID: PMC3775650)
38. Lee HK, Gautier M, Yu BC, Polito FA, Brough TJ, Szczepiorkowski ZM. Persistent increased troponin T in patient with thrombotic thrombocytopenic purpura responsive to treatment. *Clin Chim Acta*. 2010 Jun 3; 411(11-12):890-1. (PMID: 20226778)
39. Pamphilon DH, Selogie E, Szczepiorkowski ZM; for the BEST Collaborative Cellular Therapies Team. Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative. *Vox Sang*. 2010 Aug 1; 99(2):168-73. (PMID: 20230598)
40. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. *J Clin Apher*. 2010 Jun; 25(3):83-177. (PMID: 20568098)
41. Blajchman MA, Glynn SA, Josephson CD, Kleinman SH; State-of-the Science Symposium Transfusion Medicine Committee. Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. *Trans Med Rev*. 2010 Oct; 24(4):259-85. Collaborator: Szczepiorkowski ZM (PMID: 20851330)
42. Meehan KR, Talebian L, Wu J, Hill JM, Szczepiorkowski ZM, Sentman CL, Ernstoff MS. Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. *Cytotherapy*. 2010 Dec; 12(8):1013-21. (PMID: 20873991) (PMCID: PMC3280590)
43. Pamphilon D, Curnow E, Belfield H, Reems JA, McMannis J, Lecchi L, Szczepiorkowski Z, McKenna D. Storage characteristics of cord blood progenitor cells: report of a multicenter study by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. *Transfusion*. 2011 Jun; 51(6):1284-90. (PMID: 21133927)
[In reply.](#)
Pamphilon D, McKenna D, Curnow E, Belfield H, Reems JA, McMannis J, Lecchi L, Szczepiorkowski Z. *Transfusion*. 2011 Sep; 51(9):2046-7
44. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, Jones MK, Christoffel T, Pellham E, Bailey SL, Slichter SJ; for the BEST Collaborative. A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7-day-stored PLT-rich plasma and buffy coat PLTs from the same subjects. *Transfusion*. 2011 Jun; 51(6):1241-9. (PMID: 21214584)

45. Dunbar NM, Szczepiorkowski ZM. Between the trash can and the freezer: donor education and the fate of cord blood. *Transfusion*. 2011 Feb; 51(2):234-6. (PMID: 21309775)
46. Josephson CD, Glynn SA, Kleinman SH, Blajchman MA; State-of-the Science Symposium Transfusion Medicine Committee. (Contributor) A multidisciplinary "think tank": the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium. *Transfusion*. 2011 Apr; 51(4):828-41. (PMID: 21496044)
47. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA, Lewis LD, Ernstoff MS. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. *J Immunother*. 2011 May; 34(4):382-9. (PMID: 21499132) (PMCID: PMC3766324)
48. Nawrot M, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Temples T, Nielsen D, Yuan N, Wognum B, Reems JA. Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative. *Transfusion*. 2011 Sep; 51(9):2001-5. (PMID: 21569039)
49. Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erickson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. *Transfusion*. 2011 Nov; 51(11):2367-76. (PMID: 21569044)
50. Talebian L, Wu JY, Fischer DA, Hill JM, Szczepiorkowski ZM, Ernstoff MS, Sentman CL, Meehan KR. Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. *Front Biosci (Elite Ed)*. 2011 Jun 1; 3:1500-8 (PMID: 21622154) (PMCID: PMC3281307)
51. Dunbar NM, Walsh SJ, Maynard KJ, Szczepiorkowski ZM. Transfusion reaction reporting in the era of hemovigilance: where form meets function. *Transfusion*. 2011 Dec; 51(12):2583-7. (PMID: 21745209)
52. Heddle NM, Fung M, Hervig T, Szczepiorkowski ZM, Torretta L, Arnold E, Lane S, Murphy MF; for the BEST Collaborative. Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). *Transfusion*. 2012 Aug; 52(8):1687-1695. (PMID: 22229518)
53. Petras ML, Dunbar NM, Filiano JJ, Braga MS, Chobanian MC, Szczepiorkowski ZM. Therapeutic plasma exchange in *Streptococcus pneumoniae*-associated hemolytic uremic syndrome: A case report. *J Clin Apher*. 2012; 27(4):212-4. (PMID: 22307916)

54. Dunbar NM, Marx-Wood CR, Maynard KJ, Ng DP, Szczepiorkowski ZM, Dumont LJ. Retrograde patient blood flow and rouleaux preventing red blood cell transfusion. *Transfusion*. 2012 Nov; 52(11):2284. (PMID: 23140428)
55. Weber LL, Dunbar NM, Dumont LJ, Szczepiorkowski ZM. Successful use of citrate anticoagulant with heparin bolus for excessive clotting during extracorporeal photopheresis. *Transfusion*. 2012 Nov; 52(11):2494-5. (PMID: 23140434)
56. Dumont LJ, Cancelas JA, Dumont DF, Siegel AH, Szczepiorkowski ZM, Rugg N, Pratt PG, Worsham DN, Hartman EL, Dunn SK, O'Leary M, Ransom JH, Michael RA, Macdonald VW. A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. *Transfusion*. 2013 Jan; 53(1):128-37. (PMID: 22671278)
57. Meehan KR, Talebian L, Tosteson TD, Hill JM, Szczepiorkowski Z, Sentman CL, Ernstoff MS. Adoptive cellular therapy using cells enriched for NKG2D(+)CD3(+)CD8(+)T cells after autologous transplantation for myeloma. *Biol Blood Marrow Transplant*. 2013 Jan; 19(1):129-37. (PMID: 22975165) (PMCID: PMC3772513)
58. Pamphilon D, Selogie E, McKenna D, Cancelas-Peres JA, Szczepiorkowski ZM, Sacher R, McMannis J, Eichler H, Garritsen H, Takanashi M, van de Watering L, Stroncek D, Reems JA. Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. *Cytotherapy*. 2013 Mar; 15(3):255-62. (PMID: 23579058)
59. Dumont LJ, Cancelas JA, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. *Transfusion*. 2013 May; 53(5):972-80. (PMID: 22882530)
60. Mehr CR, Gupta R, von Recklinghausen FM, Szczepiorkowski ZM, Dunbar NM. Balancing risk and benefit: maintenance of a thawed Group A plasma inventory for trauma patients requiring massive transfusion. *J Trauma Acute Care Surg*. 2013 Jun; 74(6):1425-31. (PMID: 23694868)
61. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the Sixth Special Issue. *J Clin Apher*. 2013 Jul; 28(3):145-284. (PMID: 23868759)
62. Estcourt LJ, Heddle N, Kaufman R, McCullough J, Murphy MF, Slichter S, Wood EM, Stanworth SJ; Biomedical Excellence for Safer Transfusion Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. *Transfusion*. 2013 Jul; 53(7):1531-43. (PMID: 23305609) - Collaborator

63. Dunbar NM, Kreuter JD, Marx-Wood CR, Dumont LJ, Szczepiorkowski ZM. Routine bacterial screening of apheresis platelets on Day 4 using a rapid test: a 4-year single-center experience. *Transfusion*. 2013 Oct; 53(10):2307-13. (PMID: 23347110)
64. Schell AM, Petras M, Szczepiorkowski ZM, Ornstein DL. Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy. *Transfus Apher Sci*. 2013 Oct; 49(2):185-8. (PMID: 23419837)
65. Dzik WH, Beckman N, Murphy MF, Delaney M, Flanagan P, Fung M, Germain M, Haspel RL, Lozano M, Sacher R, Szczepiorkowski Z, Wendel S. Factors affecting red blood cell storage age at the time of transfusion. *Transfusion*. 2013 Dec; 53(12):3110-9. (PMID: 23550702)
66. Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM, Winters JL. Thrombotic Thrombocytopenic Purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. *J Clin Apher*. 2014 Jun; 29(3):148-67. (PMID: 24136342)
67. Yerrabothala S, Desrosiers KP, Szczepiorkowski ZM, Dunbar NM. Significant reduction in red blood cell transfusions in a general hospital after successful implementation of a restrictive transfusion policy supported by prospective computerized order auditing. *Transfusion*. 2014 Oct; 54(10 Pt 2):2640-5. (PMID: 24673396)
68. Morgan SM, Shaz BH, Pavenski K, Meyer EK, Delaney M, Szczepiorkowski ZM. The top clinical trial opportunities in therapeutic apheresis and neurology. *J Clin Apher*. 2014 Dec; 29(6):331-5. (PMID: 24899381)
69. Nahirniak S, Slichter SJ, Tanael S, Rebullia P, Pavenski K, Vassallo R, Fung M, Duquesnoy R, Saw CL, Stanworth S, Tinmouth A, Hume H, Ponnampalam A, Moltzan C, Berry B, Shehata N; International Collaboration for Transfusion Medicine Guidelines. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. *Transfus Med Rev*. 2015 Jan; 29(1):3-13. (PMID: 25537844)
(Szczepiorkowski ZM - member of the *International Collaboration for Transfusion Medicine Guidelines*)
70. Dumont LJ, Cancelas JA, Maes LA, Rugg N, Whitley P, Herschel L, Siegel AH, Szczepiorkowski ZM, Hess JR, Zia M. The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection. *Transfusion*. 2015 Mar; 55(3):476-84. (PMID: 25233805)
71. Dumont LJ, Cancelas JA, Maes LA, Rugg N, Whitley P, Herschel L, Siegal AH, Szczepiorkowski ZM, Hess JR, Zia M. Overnight, room temperature hold of whole blood followed by 42-day storage of red blood cells in additive solution-7. *Transfusion*. 2015 Mar; 55(3):485-90. (PMID: 25234026)

72. Dunbar NM, Katus MC, Freeman CM, Szczepiorkowski ZM. Easier said than done: ABO compatibility and D matching in apheresis platelet transfusions. *Transfusion*. 2015 Aug; 55(8):1882-8. (PMID: 25757728)
73. Weber LL, Dunbar NM, Meehan KR, Szczepiorkowski ZM, Lansigan F. Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital. *J Clin Apher*. 2015 Dec; 30(6):359-63. (PMID: 25691106)
74. D'Alessandro A, Nemkov T, Hansen KC, Szczepiorkowski ZM, Dumont LJ. Red blood cell storage in additive solution-7 preserves energy and redox metabolism: a metabolomics approach. *Transfusion*. 2015 Dec; 55(12):2955-66. PMID: 26271632
75. Martin IW, Martin CL, Dunbar NM, Lee SL, Szczepiorkowski ZM. Therapeutic plasma exchange as a steroid-sparing therapy in a patient with limbic encephalitis due to antibodies to voltage-gated potassium channels. *J Clin Apher*. 2016 Feb; 31(1):63-5. (PMID: 25851808)
76. Dumont LJ, D'Alessandro A, Szczepiorkowski ZM, Yoshida T. CO₂ -dependent metabolic modulation in red blood cells stored under anaerobic conditions. *Transfusion*. 2016 Feb; 56(2):392-403. PMID: 26477888
77. Dunbar NM, Dumont LJ, Szczepiorkowski ZM. How do we implement Day 6 and Day 7 platelets at a hospital-based transfusion service? *Transfusion*. 2016 Jun; 56(6):1262-6. PMID: 27018564
78. Martin IW, Katus MC, Martin CL, Szczepiorkowski ZM, Gorham JD, Dunbar NM. Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia. *J Clin Apher*. 2016 Oct; 31(5):419-22. PMID: 26332753
79. Dunbar NM, Raval JS, Johnson A, Abikoff CM, Adamski J, Cooling LL, Grossman B, Kim HC, Marques MB, Morgan S, Schmidt AE, Sloan SR, Su LL, Szczepiorkowski ZM, West FB, Wong E, Schneiderman J. Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. *J Clin Apher*. 2017 Aug;32(4):215-223. PMID: 27442906
80. Alquist CR, Szczepiorkowski ZM, Dunbar N. Babesia parasitemia rebound after red blood cell exchange. *J Clin Apher*. 2017 Aug;32(4):276-278. PMID: 27583822
81. Dunbar NM, Olson NJ, Szczepiorkowski ZM, Martin ED, Tysarczyk RM, Triulzi DJ, Alarcon LH, Yazer MH. Blood component transfusion and wastage rates in the setting of massive transfusion in three regional trauma centers. *Transfusion*. 2017 Jan;57(1):45-52. PMID: 27774614
82. D'Alessandro A, Gray AD, Szczepiorkowski ZM, Hansen K, Herschel LH, Dumont LJ. Red blood cell metabolic responses to refrigerated storage, rejuvenation, and frozen storage. *Transfusion*. 2017 Apr;57(4):1019-1030. PMID: 28295356

83. Worsham DN, Reems JA, Szczepiorkowski ZM, McKenna DH, Leemhuis T, Mathew AJ, Cancelas JA; Biomedical Excellence for Safer Transfusion (BEST) Collaborative Group. Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations. *Transfusion*. 2017 Jun;57(6):1555-1565. PMID: 28453219
84. Alquist CR, Szczepiorkowski ZM. Transfusion Service Observations: Red Blood Cell Surname-Antibody Pairings. *Ochsner J*. 2017 Summer;17(2):134-135. PMID:28638282
PMCID: PMC5472068
85. Linnik YA, Tsui EW, Martin IW, Szczepiorkowski ZM, Denomme GA, Gottschall JL, Hill JM Jr, Dunbar NM. The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia. *Transfusion*. 2017 Dec;57(12):2937-2941. PMID: 28905389
86. Coker SA, Szczepiorkowski ZM, Siegel AH, Ferrari A, Mambrini G, Anand R, Hartman RD, Benatti L, Dumont LJ. A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers. *Transfus Med Rev*. 2018 Apr;32(2):102-110. PMID:29031409
87. Yerrabothala S, Talebian L, Klinker K, Hickman J, Hill JM, Hayes C, Lowrey C, Szczepiorkowski ZM, Meehan KR. Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization. *J Clin Apher*. 2018 Jun;33(3):310-315. PMID:29193271
88. Gniadek TJ, Garritsen HSP, Stroncek D, Szczepiorkowski ZM, McKenna DH; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Optimal Storage Conditions for Apheresis Research (OSCAR): a Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. *Transfusion*. 2018 Feb;58(2):461-469. PMID:29210068
89. Maloney N, Martin I, Szczepiorkowski ZM, Dunbar NM. Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia. *J Clin Apher*. 2018 Jun;33(3):436-438. PMID:29270999
90. Harm SK, Szczepiorkowski ZM, Dunbar NM. Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation. *Transfusion*. 2018 Apr;58(4):938-942. PMID:29332317
91. Szczepiorkowski ZM, Burnett CA, Dumont LJ, Abhyankar SH. Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. *Transfusion*. 2018 Apr;58(4):943-950. PMID:29451308
92. Ruby KN, Thomasson RR, Szczepiorkowski ZM, Dunbar NM. Bacterial screening of apheresis platelets with a rapid test: a 113-month single center experience. *Transfusion*. 2018 Jul;58(7):1665-1669. PMID:29664170

93. Ward SJ, Stramer SL, Szczepiorkowski ZM. Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: Report of AABB's Ad Hoc Babesia Policy Working Group (original report). *Transfusion* 2018 Aug;58(8):1916-1923. PMID: 30180272 (editorial by Dr. Beth Shaz in the same issue)
94. Slichter SJ, Dumont LJ, Cancelas JA, Jones ML, Gernsheimer TB, Szczepiorkowski ZM, Dunbar NM, Prakash G, Medlin S, Rugg N, Kinne B, Macdonald VW, Housler G, Valiyaveettil M, Hmel P, Ransom JH. Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. *Transfusion* 2018 Sep;58(9):2129-2138. PMID: 30204953
95. Takanashi M, Selogie E, Reems JA, Stroncek D, Fontaine MJ, Girdlestone J, Garritsen HSP, Young P, McKenna DH, Szczepiorkowski ZM; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. *Transfusion* 2018 Sep;58(9):2184-2191. PMID: 30204955
96. Kjaer M, Bertrand G, Bakchoul T, Massey E, Baker JM, Lieberman L, Tanael S, Greinacher A, Murphy MF, Arnold DM, Baidya S, Bussel J, Hume H, Kaplan C, Oepkes D, Ryan G, Savoia H, Shehata N, Kjeldsen-Kragh J; International Collaboration for Transfusion Medicine Guidelines (Dr. Szczepiorkowski is the member of ICTMG). Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. *Vox Sang.* 2019 Jan;114(1):79-94. PMID: 30565711
97. Boada M, Lopez O, Nunez L, Szczepiorkowski ZM, Torres M, Grifols C, Paez T. Plasma Exchange for Alzheimer's Disease Management by Albumin Replacement (AMBAR) Trial: Study design and progress. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 5 (2019) 61-69
PMID: 30859122
98. Baker JM, Shehata N, Bussel J, Murphy MF, Greinacher A, Bakchoul T, Massey E, Lieberman L, Landry D, Tanael S, Arnold DM, Baidya S, Bertrand G, Kjaer M, Kaplan C, Kjeldsen-Kragh J, Oepkes D, Savoia H, Ryan G, Hume H; International Collaboration for Transfusion Medicine Guidelines (ICTMG)
(Dr. Szczepiorkowski is the member of ICTMG). Postnatal intervention for the treatment of FNAIT: a systematic review. *J Perinatol.* 2019 Apr 10. Doi: 10.1038/s41372-019-0360-7 [Epub ahead of print] Review
PMID: 30971767
99. Fontaine MJ, Selogie E, Stroncek D, McKenna D, Szczepiorkowski ZM, Takanashi M, Garritsen H, Girdlestone J, Reems JA; Biomedical Excellence for Safer Transfusion (BEST) Collaborative Variations in novel cellular therapy products manufacturing. *Cytotherapy.* 2020 Jun;22(6):337-342. doi: 10.1016/j.jcyt.2020.01.012. Epub 2020 Mar 27. PMID: 32223996
100. Thibodeaux SR, McKenna DH, Szczepiorkowski ZM, Fontaine MJ, Kelley L, Reems JA, Young PP; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. A

- multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity. *Transfusion*. 2020 Aug;60(8):1811-1820. doi: 10.1111/trf.15899. Epub 2020 Jul 12. PMID:32654200
101. Boada M, López OL, Olazarán J, Núñez L, Pfeffer M, Paricio M, Lorites J, Piñol-Ripoll G, Gámez JE, Anaya F, Kiprof D, Lima J, Grifols C, Torres M, Costa M, Bozzo J, Szczepiorkowski ZM, Hendrix S, Páez AA randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. *Alzheimers Dement*. 2020 Oct;16(10):1412-1425. doi: 10.1002/alz.12137. Epub 2020 Jul 27. PMID: 32715623 Free PMC article.
 102. Hubbard JA, Geno KA, Khan J, Szczepiorkowski ZM, de Gijssel D, Ovalle AA, AlSalman AS, Gallagher TL, Johnston AA, Tibbetts AR, Vital SE, Cervinski MA, Nerenz RD. Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies. *J Appl Lab Med*. 2021 Mar 1;6(2):429-440. doi: 10.1093/jalm/jfaa175. PMID: 32976593 Free PMC article.
 103. Viswanathan S, Ciccocioppo R, Galipeau J, Krampera M, Le Blanc K, Martin I, Moniz K, Nolta J, Phinney DG, Shi Y, Szczepiorkowski ZM, Tarte K, Weiss DJ, Ashford P. Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. *Cytotherapy*. 2021 Dec;23(12):1060-1063. doi: 10.1016/j.jcyt.2021.04.009. Epub 2021 Jun 9. PMID: 34116944
 104. Boada M, López OL, Olazarán J, Núñez L, Pfeffer M, Puente O, Piñol-Ripoll G, Gámez JE, Anaya F, Kiprof D, Alegret M, Grifols C, Barceló M, Bozzo J, Szczepiorkowski ZM, Páez A; AMBAR Trial Group. Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. *Alzheimers Dement*. 2021 Nov 2. doi: 10.1002/alz.12477. Online ahead of print. PMID: 34726348
 105. Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. *Am J Hematol*. 2022 Mar 1;97(3):256-266. doi: 10.1002/ajh.26403. Epub 2021 Dec 23. PMID: 34748664
 106. Toledo DM, Robbins AA, Gallagher TL, Hershberger KC, Barney RE, Salmela SM, Pilcher D, Cervinski MA, Nerenz RD, Szczepiorkowski ZM, Tsongalis GJ, Lefferts JA, Martin IW, Hubbard JA. Wastewater-Based SARS-CoV-2 Surveillance in Northern New England. *Microbiol Spectr*. 2022 Apr 27;10(2):e0220721. doi: 10.1128/spectrum.02207-21. Epub 2022 Apr 12. PMID: 35412387
 107. Cancelas JA, Genthe JR, Stolla M, Rugg N, Bailey SL, Nestheide S, Shaz B, Mack S, Schroeder K, Anani W, Szczepiorkowski ZM, Dumont LJ, Yegneswaran S, Corash L, Mufti

- N, Benjamin RJ, Erickson AC. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage. *Transfusion*. 2022 Aug;62(8):1619-1629. doi: 10.1111/trf.17003. Epub 2022 Jul 9. PMID: 35808974
108. Ondrasik RM, Khan J, Szczepiorkowski ZM, Levy JJ, Dunbar NM Passive order auditing associated with reductions in red blood cell utilization: National blood shortage experience. *Transfusion*. 2022 Aug;62(8):1551-1558. doi: 10.1111/trf.17008. Epub 2022 Jul 11. PMID: 35815525
109. Karafin MS, DeSimone RA, Dvorak J, Metcalf RA, Pagano MB, Park YA, Schwartz J, Souers RJ, Szczepiorkowski ZM, Uhl L, Ramsey G Antibody Titers in Transfusion Medicine: A Critical Reevaluation of Testing Accuracy, Reliability, and Clinical Use. *Arch Pathol Lab Med*. 2023 Feb 2. doi: 10.5858/arpa.2022-0248-CP. Online ahead of print. PMID: 36730468
110. Grifols C, Barceló M, Núñez L, Szczepiorkowski ZM, Boada M, López OL, Páez A Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study. *Ther Apher Dial*. 2023 May 21. doi: 10.1111/1744-9987.14002. Online ahead of print. PMID: 37211527
111. Ramsey G, Park YA, Eder AF, Bobr A, Karafin MS, Karp JK, King KE, Pagano MB, Schwartz J, Szczepiorkowski ZM, Souers RJ, Thomas L, Delaney M. Obstetric and Newborn Weak D-Phenotype RBC Testing and Rh Immune Globulin Management Recommendations: Lessons From a Blinded Specimen-Testing Survey of 81 Transfusion Services. *Arch Pathol Lab Med*. 2023 Jan 1;147(1):71-78. doi: 10.5858/arpa.2021-0250-CP. PMID: 35486492
112. Boada M, Kiproff D, Anaya F, López OL, Núñez L, Olazarán J, Lima J, Grifols C, Barceló M, Rohe R, Prieto-Fernández C, Szczepiorkowski ZM, Páez A Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study. *J Clin Apher*. 2023 Feb;38(1):45-54. doi: 10.1002/jca.22026. Epub 2022 Oct 28. PMID: 36305459
113. Karafin MS, DeSimone RA, Dvorak J, Metcalf RA, Pagano MB, Park YA, Schwartz J, Souers RJ, Szczepiorkowski ZM, Uhl L, Ramsey G. Antibody Titers in Transfusion Medicine: A Critical Reevaluation of Testing Accuracy, Reliability, and Clinical Use. *Arch Pathol Lab Med*. 2023 Dec 1;147(12):1351-1359. doi: 10.5858/arpa.2022-0248-CP. PMID: 36730468
114. Grifols C, Barceló M, Núñez L, Szczepiorkowski ZM, Boada M, López OL, Páez A. Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study. *Ther Apher Dial*. 2023 Oct;27(5):949-959. doi: 10.1111/1744-9987.14002. Epub 2023 May 21. PMID: 37211527

115. Lachert E, Antoniewicz-Papis J, Mikołowska A, Kubis J, Szczepiorkowski ZM, Łętowska M. Introduction of EUBIS standards to upgrade inspections of blood establishments to improve the safety of blood transfusion: The Polish experience. *Transfus Med.* 2023 Dec;33(6):460-466. doi: 10.1111/tme.13007. Epub 2023 Sep 21. PMID: 37732379
116. Callum J, Skubas NJ, Bathla A, Keshavarz H, Clark EG, Rochweg B, Fergusson D, Arbous S, Bauer SR, China L, Fung M, Jug R, Neill M, Paine C, Pavenski K, Shah PS, Robinson S, Shan H, Szczepiorkowski ZM, Thevenot T, Wu B, Stanworth S, Shehata N; International Collaboration for Transfusion Medicine Guidelines Intravenous Albumin Guideline Group. Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines. *Chest.* 2024 Mar 4:S0012-3692(24)00285-X. doi: 10.1016/j.chest.2024.02.049. Online ahead of print. PMID: 38447639

///

Reviews:

1. Laposata M, Szczepiorkowski ZM, Brown JE. Fatty acid ethyl esters: non-oxidative metabolites of ethanol. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 1995; 52(2-3):87-91. (PMID: 7784463)
2. Szczepiorkowski ZM and Nguyen PL. The White Blood Cell Differential – When Is It Useful Turnaround Times 5(2):1-5, 1996.
3. Szczepiorkowski ZM and Vamvakas EC. Therapeutic Apheresis: The Exchange or Removal of Blood Components as a Treatment for Disease. *Turnaround Times* 6(2):1-6, 1997.
4. Szczepiorkowski ZM and Dunbar NM. Transfusion guidelines: when to transfuse. *Hematology Am Soc Hematol Educ Program*. 2013; 2013:638-44. (PMID: 24319244)
5. Benjamin RJ, McDonald CP; ISBT Transfusion Transmitted Infectious Disease Bacterial Workgroup. The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines. *Transfus Med Rev*. 2014 Apr; 28(2):61-71. (PMID: 24636779)
(Szczepiorkowski ZM - member of the TTID Bacterial Workgroup)
6. Katus MC, Szczepiorkowski ZM, Dumont LJ, Dunbar NM. Safety of platelet transfusion: past, present and future. *Vox Sang*. 2014 Aug; 107(2):103-13 (PMID: 24650183)
7. Dunbar NM, Szczepiorkowski ZM. Hardwiring patient blood management: harnessing information technology to optimize transfusion practice. *Curr Opin Hematol*. 2014 Nov; 21(6):515-20. (PMID: 25295746)
8. Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, Levine JE, Morgan S, Schneiderman J, Sloan S, Wu Y, Szczepiorkowski ZM, Cooling L; American Society for Apheresis. National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. *Transfus Med Rev*. 2015 Jan; 29(1):62-70. (PMID: 25459074)
9. Dunbar NM, Szczepiorkowski ZM. How do we utilize a transfusion safety officer? *Transfusion*. 2015 Sep; 55(9):2064-8. (PMID: 26033515)
10. Szczepiorkowski ZM Indications for therapeutic apheresis in hematological disorders..*Semin Hematol*. 2020 Apr;57(2):57-64. doi: 0.1053/j.seminhematol.2020.07.008. Epub 2020 Jul 25.PMID: 32892844 Review.
11. Kelly K, Cancelas JA, Szczepiorkowski ZM, Dumont DF, Rugg N, Dumont LJ. Frozen Platelets-Development and Future Directions. *Transfus Med Rev*. 2020 Oct;34(4):286-293. doi: 10.1016/j.tmr.2020.09.008. Epub 2020 Sep 22.PMID: 33317698 Review.

12. Ashford P, Allman S, Larsson S, Loper K, Moniz K, Sims-Poston L, Slaper-Cortenbach I, Szczepiorkowski ZM. Standardization of cellular therapy terminology, coding and labeling: a review. *Cytotherapy*. 2022 Mar 31:S1465-3249(22)00074-3. doi 10.1016/j.jcyt.2022.02.009. Online ahead of print.PMID: 35370094
13. Szczepiorkowski ZM, Pagano MB Platelet components and bacterial contamination: hospital perspective 2022.. *Hematology Am Soc Hematol Educ Program*. 2022 Dec 9;2022(1):430-436. doi: 10.1182/hematology.2022000402.PMID: 36485080

Book chapters:

1. Szczepiorkowski ZM and Sacher RA. Autoimmune Hemolytic Anemia in 2000 Conn's Current Therapy. Ed. Robert E. Rakel, W.B. Saunders, Philadelphia, PA, 2000.
2. Szczepiorkowski ZM and Stowell CP. Red Blood Cell Substitutes in Blood Safety and Surveillance. Ed. Linden J and Bianco C, Marcel Dekker, Inc., NY, 2001.
3. Szczepiorkowski ZM and Laposata M. Fatty Acid Ethyl Esters: Nonoxidative Metabolites of Ethyl Alcohol and Fatty Acids in Fatty Acids: Physiological and Behavioral Functions. Eds. DI Mostofsky, S Yehuda, and N Salem, Humana Press, NJ, 2001.
4. Szczepiorkowski ZM. QA/QC for Testing of New Products in the Current Perspectives in Cellular Therapy 2002. Eds. Szczepiorkowski ZM and Snyder EL. AABB Press, Bethesda, MD, 2001.
5. Szczepiorkowski ZM. Cytokines in the Current Perspectives in Cellular Therapy 2002. Eds. Szczepiorkowski ZM and Snyder EL. AABB Press, Bethesda, MD, 2001.
6. Szczepiorkowski ZM and Lewandrowski KB. Renal Function and Nitrogen Metabolites in the Clinical Chemistry: Laboratory Management and Clinical Correlations. Ed. Kent Lewandrowski. Lippincott Williams and Wilkins, New York, NY, 2002
7. Szczepiorkowski ZM. Antiphospholipid Antibody Syndrome – case study. In. Rossi's Principles of Transfusion Medicine. Eds. Simon T, Dzik W, Snyder E, Stowell CP, Strauss RG, 3rd edition. Lippincott, Williams and Wilkins, Philadelphia, PA, 2002
8. Szczepiorkowski ZM. Methods. In Laboratory Medicine: Clinical Pathology in the Practice of Medicine. ed. M Laposata. ASCP Press, Chicago, IL 2002 (new front matter is available at [HUhttp://www.ascp.org/511live/Timssnet/products/TNTproducts.cfm](http://www.ascp.org/511live/Timssnet/products/TNTproducts.cfm) as of 11/3/05UH; or from ZMS)
9. Dzik S and Szczepiorkowski ZM. Leukocyte reduced products in the Blood Banking and Transfusion Medicine. Eds. Hillyer C, Silberstein L, Anderson K, and Ness P. Elsevier Science Philadelphia, PA, 2003.
10. Szczepiorkowski ZM. TPE in Renal, Rheumatic, and Miscellaneous Disorders In Apheresis: Principles and Practice, 2nd edition. Eds. McLeod BC, Price TH, and Weinstein R. AABB Press, Bethesda, MD 2003

11. Eichbaum Q and Szczepiorkowski ZM. Dendritic Cell Immunotherapy. In Emerging Technologies in Transfusion Medicine. Eds. Stowell CP and Dzik WH. AABB Press, Bethesda, MD 2003
12. Szczepiorkowski ZM and Bhardwaj N. Dendritic Cell Biology. In Hematology: Basic Principles and Practice, 4th edition. Eds Hoffman R, Benz EJ, Shattil S, Furie B, Cohen HJ, Silberstein LE, and McGlave P. Elsevier Science/Churchill Livingstone, Philadelphia, PA 2004.
13. Szczepiorkowski ZM. Adoptive Immunotherapy (Dendritic Cell and T-cell Mediated Therapy) In Cellular Therapy; A primer for Medical Professionals. Eds. Snyder EL and Haley NR. AABB Press, 2004.
14. Szczepiorkowski ZM. Development of Cellular Therapy Standards. In Cellular Therapy; A primer for Medical Professionals. Eds. Snyder EL and Haley NR. AABB Press, 2004
15. Dzik S and Szczepiorkowski ZM. Leukocyte reduced products in the Blood Banking and Transfusion Medicine. 2nd edition. Eds. Hillyer C, Silberstein L, Anderson K, and Ness P. Elsevier Science Philadelphia, PA, 2006.
16. Szczepiorkowski ZM. Transfusion Support for Hematopoietic Transplant Recipients. Technical Manual. 16th Edition. Ed J Roback; AABB Press, 2008.
17. Nunez E and Szczepiorkowski ZM. AABB Accreditation in Cellular Therapy in Cellular Therapy Handbook, Ed. A. Gee Springer Verlag. 2009
18. Meyer EK and Szczepiorkowski ZM. Transfusion Support for HSCT recipients. In Bone Marrow Transplantation – Clinical Handbook. Ed. Wingard J, Gastineau D, Leather H, Snyder E, Szczepiorkowski ZM. AABB Press; 2009. 207-226.
19. Manches O, Lakshmanan V, Szczepiorkowski ZM, Bhardwaj N, Dendritic Cell Biology. In Hematology: Basic Principles and Practice, 5th edition. Eds Hoffman R, Furie B, McGlave P, Silberstein LE, Shattil S, Benz EJ, and Heslop H. Elsevier Science/Churchill Livingstone, Philadelphia, PA 2009.
20. Bushnell, KM and Szczepiorkowski ZM. Receipt, Processing and Infusion of Hematopoietic Progenitor and Therapeutic Cells. In Apheresis Principles and Practice, 3rd Edition Eds. McLeod BC; Szczepiorkowski ZM, Weinstein R, and Winters JL. AABB Press 2010
21. Szczepiorkowski ZM Cytapheresis. In Therapeutic Apheresis. A Physician's Handbook. 3rd Edition. Editor: Winters JL. AABB. 2011(also contributing editor)
22. Manches O, Lakshmanan V, Szczepiorkowski ZM, Bhardwaj N, Dendritic Cell Biology. In Hematology: Basic Principles and Practice, 6th edition. Eds Hoffman R, Benz EJ,

- Silberstein LE, and Heslop H. Elsevier Science/Churchill Livingstone, Philadelphia, PA 2012.
23. Pamphilon DH and Szczepiorkowski ZM. Regulation and accreditation in cellular therapy. In Practical Transfusion Medicine. 4th edition. Eds. Murphy MF, Pamphilon DH, and Heddle HM. Willey-Blackwell, Oxford, UK. 2013
 24. El-Ghariani K. and Szczepiorkowski ZM. Stem cell collection and therapeutic apheresis. In Practical Transfusion Medicine. 4th edition. Eds. Murphy MF, Pamphilon DH, and Heddle HM. Willey-Blackwell, Oxford, UK. 2013
 25. Devine DV, Dzik WH, and Szczepiorkowski ZM. Scanning the future of transfusion medicine. In Practical Transfusion Medicine. 4th edition. Eds. Murphy MF, Pamphilon DH, and Heddle HM. Willey-Blackwell, Oxford, UK. 2013
 26. Szczepiorkowski ZM Cytapheresis. In Therapeutic Apheresis. A Physician's Handbook. 4th Edition. Editor: Winters JL King K. AABB. 2013 (also contributing editor)
 27. Meyer EK and Szczepiorkowski ZM. Transfusion Support for Hematopoietic Stem Cell Transplantation. In Hematopoietic Stem Cell Transplantation – A Handbook for Clinicians 2nd Edition Ed. Wingard JR, Gastineau DA, Leather HL, Snyder EL, Szczepiorkowski ZM. AABB; 2015. 291-314.
 28. Sugrue MW, Szczepiorkowski ZM and Gastineau DA. Accreditation Standards and Quality Programs in Hematopoietic Stem Cell Transplantation. In Hematopoietic Stem Cell Transplantation – A Handbook for Clinicians 2nd Edition Ed. Wingard JR, Gastineau DA, Leather HL, Snyder EL, Szczepiorkowski ZM. AABB; 2015. 819-836.
 29. Rosiek A, Szczepiorkowski ZM. Lecznicze Zabiegi Aferezy i Terapia Komorkowa. [Polish] In Hematologia. Ed. Robak T and Warzocha K Via Medica, Gdansk, Poland 2016; 340-351. ISBN: 978-83-65476-41-8
 30. Sharma P and Szczepiorkowski ZM. Ethical Issues in Adult and Pediatric Hematopoietic Stem Cell Mobilization and Collection. In Ethical Issues in Transfusion Medicine and Cellular Therapies. 2nd edition. Ed. Domen R. AABB Press; 2015, 73-98; ISBN: 9781563959097
 31. Szczepiorkowski ZM and Hollyman D. Regulation and accreditation in cellular therapy. In Practical Transfusion Medicine. 5th edition. Eds. Murphy MF, Roberts D, and Yezer M. Willey-Blackwell, Oxford, UK. 2017 ISBN: 9781119129417
 32. El-Ghariani K. and Szczepiorkowski ZM. Stem cell collection and therapeutic apheresis. In Practical Transfusion Medicine. 5th edition. Eds. Murphy MF, Roberts D, and Yezer M. Willey-Blackwell, Oxford, UK. 2017 ISBN: 9781119129417

33. Szczepiorkowski ZM Cytapheresis. In Therapeutic Apheresis. A Physician's Handbook. 5th Edition. Editor: Crookston K. AABB. 2017 (also contributing editor) 67-110. ISBN: 978-1-56395-931-8

/// Additional chapters from Practical Transfusion (2) and Apheresis Book (3) in print

B. Other scholarly work in print or other media

Letters to the editor:

1. Scott SM, Szczepiorkowski ZM. Rituximab for TTP. Am J Hematol 2005 Sep; 80(1):87-88. (PMID: 16138332)
2. Winters JL, Shaz BH, Szczepiorkowski ZM. Plasma exchange in pancreatitis due to hypertriglyceridemia. Transfusion 2009 May; 49(5):1022-3. (PMID: 19426205)
3. Petras ML, Leach MK, Szczepiorkowski ZM, Dunbar NM. Red blood cell alloantibodies: a 45-year historical review at a rural tertiary care center. Transfusion. 2012 Jun; 52(6):1380-2. (PMID: 22686534)
4. Dunbar NM, Marx-Wood CR, Maynard KJ, Ng DP, Szczepiorkowski ZM, Dumont LJ. Retrograde patient blood flow and rouleaux preventing red blood cell transfusion. Transfusion. 2012 Nov;52(11):2284. (PMID: 23140428)
5. Dumont LJ, Szczepiorkowski ZM. Pooled platelet concentrates or apheresis platelets? N Engl J Med. 2013 May 9; 368(19):1848-9. (PMID: 23656664)
6. Shaz BH, Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Szczepiorkowski ZM, Williams ME, Wu Y, Linenberger ML. American Society for Apheresis guidelines support use of red cell exchange transfusion for severe malaria with high parasitemia. Clin Infect Dis. 2014 Jan; 58(2):302-3. (PMID: 24092801)
7. Raasch Alquist C, Root L, Dunbar N, Szczepiorkowski ZM. Highlighting oft-overlooked granulocyte-colony-stimulating factor kinetics. Transfusion. 2016 Jun; 56(6):1484-5. (PMID: 27264014)

Editorials, Book Editor:

1. Szczepiorkowski ZM and Snyder EL. Editor Current Perspectives in Cellular Therapy 2002. AABB Press, Bethesda, MD, 2001.
2. Szczepiorkowski ZM ed. Standards for Cellular Therapy Services. Bethesda, MD: American Association of Blood Banks, 2004
3. Szczepiorkowski ZM ed. Standards for Cellular Therapy Services. 2nd Edition Bethesda, MD: American Association of Blood Banks, 2007

4. Szczepiorkowski ZM, Guest Editor. The ASFA Special Issue. 4th Edition. J of Clin Apheresis, 22(3), 2007.
5. Szczepiorkowski ZM, Dumont LJ. Hematopoietic stem cell transplantation: is ABO “a match made in heaven”? Transfusion 2009 Apr; 49(4):612-4. PMID: 19335373
6. Fox-Cutler M, Snyder E, Szczepiorkowski ZM – Section Editor, in Cellular Therapy Principles. Ereman E. AABB Press. 2009
7. Wingard J, Gastineau D, Leather H, Snyder E, Szczepiorkowski ZM – Co-editor, Hematopoietic Stem Cell Transplantation. A Handbook for Clinicians. AABB Press, 2009
8. McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL – Co-editor, Apheresis: Principles and Practice, 3rd edition, AABB Press 2010
9. Szczepiorkowski ZM and Shaz BH and Guest Co-Editors. The ASFA Special Issue. 5th Edition. J of Clin Apheresis, 25(3), 2010.
10. Dunbar NM and Szczepiorkowski ZM. Between the trash can and the freezer: donor education and the fate of cord blood. Transfusion 2011 Feb; 51(2):234-6. (PMID: 21309775)
11. Wingard J, Gastineau D, Leather H, Snyder E, Szczepiorkowski ZM – Co-editor, Hematopoietic Stem Cell Transplantation. 2nd Edition A Handbook for Clinicians. AABB, 2015
12. Szczepiorkowski ZM, McCullough J, Triulzi DJ. Primum non confundere: whole blood versus apheresis platelet debate continues. Transfusion. 2016 Jun; 56(6):1254-7. (PMID: 27264009)
13. Annen K, Zubair A, Schwartz E, Schwartz J, Szczepiorkowski ZM. What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR-T therapy. J Clin Apher. 2020 Jun;35(3):234-235. doi: 10.1002/jca.21776. Epub 2020 Mar 18. PMID: 32186782 No abstract available.

C. Abstracts: Include both oral, exhibit and poster presentations.

Presented at National Meetings:

1. Szczepiorkowski ZM, Teruya J, and Laposata M. Relative availability of linoleate-derived arachidonate and arachidonate not derived from precursor fatty acid for icosanoid production. Third Annual Mid-Atlantic Lipid Research Symposium, Atlantic City, NJ, USA, 1991
2. Teruya J, Szczepiorkowski ZM, and Laposata M. Mode of fatty acid transport to endothelial cells influences intracellular fatty acid metabolism. Third Annual Mid-Atlantic Lipid Research Symposium. Atlantic City, NJ, 1991

3. Szczepiorkowski ZM, Dickersin GR, and Laposata M. Fatty acid ethyl esters decrease human hepatoblastoma cell proliferation and protein synthesis. Sixth Annual Mid-Atlantic Lipid Research Symposium. Atlantic City, NJ, 1994.
4. Szczepiorkowski ZM, Ritzenthaler J, and Stowell CP. The use of TPE in a patient with antiphospholipid antibody syndrome complicated by pulmonary alveolar hemorrhage. [Abstract], Journal of Clinical Apheresis 14:92, 1999.
5. Szczepiorkowski ZM, Scadden DT, Ritzenthaler J, and Stowell CP. Recurrent thrombotic thrombocytopenic purpura in a patient with HIV infection. [Abstract], Journal of Clinical Apheresis 14:93, 1999.
6. Linette, G, Jonasch E, Longerich S, Yang S, Webb I, Szczepiorkowski Z, Chung A, Fee S, Haluska F. Phase I study of therapy with peptide-pulsed autologous dendritic cells for advanced melanoma. [Abstract] ASCO on line, 2000.
7. Adams GB, Olson DP, Szczepiorkowski ZM, Kos C, Pollack MR, Clingensmith BL, Brown EM, Scadden DT. Bone Mineral Contributes to Bone Marrow Hematopoiesis Through the Calcium Sensing Receptor. [Abstract] ASH Meeting 2001, Orlando, FL
8. Fugazzotto J, Bissonnette JP, Ritzenthaler J, Szczepiorkowski ZM. Recurrent thrombotic thrombocytopenic purpura in a patient in the very early pregnancy treated by plasmapheresis and plasma infusions. [Abstract] Journal of Clinical Apheresis 17:146, 2002.
9. Ritzenthaler J, Arrighi J, Stowell CP, Szczepiorkowski ZM. Comparison of plateletpheresis using two automated separators at a hospital based donor center. J Clin Apheresis 2003;18:82 (This abstract was awarded Allied Health Award for the best abstract at the ASFA Annual Meeting in Lake Tahoe, CA, 2003)
10. Eichbaum Q, Foran S, Dzik WH, Chung R, Szczepiorkowski ZM. Therapeutic erythrocytapheresis in a liver allograft recipient with erythropoietic protoporphyria and liver failure. J Clin Apheresis 2003;18:82-83.
11. Dobrusin I, Kirchoff K, Ritzenthaler J, Szczepiorkowski ZM. Peripheral blood progenitor cell collections: Introduction of quality measures for collection personnel. J Clin Apheresis 2003;18:83.
12. Ritzenthaler J, Szczepiorkowski ZM. The role of therapeutic erythrocytapheresis in the treatment of infection with Babesia microti in patients with significant co-morbidities. J Clin Apheresis 2003;18:95.
13. Dobrusin I, Ritzenthaler J, Stowell CP, Szczepiorkowski ZM. In-time review of PBSC collection results with apheresis operators improves the quality of the final product. J Clin Apheresis 2004;19:29.

14. Ritzenthaler J, Divito P, Fennessy G, Szczepiorkowski ZM, Stowell CP. Effect of quantitating platelet yields on the day vs. the day after collection of platelets, apheresis. *J Clin Apheresis* 2004;19:43.
15. Gandhi RT, Shopis J, Altfeld M, Rosenberg E, Szczepiorkowski ZM, Jacobson J, Bhardwaj N. Immunotherapy with Dendritic Cell Vaccines in HIV Infected Individuals. Doris Duke Research Foundation Meeting, Spring 2004
16. Feeney DM, Ritzenthaler JM, Divito P, Stolyarova N, McDonough A, Stowell CP, Szczepiorkowski ZM. Comparison of Two Apheresis Based Method used to Harvest Source Leukocytes to Whole Blood Derived Buffy Coats for use in Bench Research. *J Clin Apheresis* 2005;20:29-30.
17. Pavelka MJ, Leach MF, Velliquette JL, AuBuchon JP, Szczepiorkowski ZM. Trends in Therapeutic Apheresis Indications in a Tertiary Hospital in a Rural Setting. *J Clin Apheresis* 2005;20:39-40.
18. Weber SM, Fisher J, Ernstoff M, Szczepiorkowski ZM. The Effect of the Quality of Mononuclear Cell Product on Elutriation and Dendritic Cell Expansion. *Cytotherapy* 2005 (7) Suppl. A157.
19. Hill JM, Webber SM, Fitzmaurice TF, Cole BF, Szczepiorkowski ZM, Meehan KR. Factors Underlying Early Lymphocyte Recovery and Associated Survival Benefit Following Autologous Stem Cell Transplant for Lymphoproliferative Disorders. *Biol Blood and Marrow Transplantation* 2005;11(2)(Suppl 1), 55.
20. Leach MF, AuBuchon JP, Szczepiorkowski, ZM. The Incidence of Positive Direct Antiglobulin Tests and Red Cell Drug Antibodies in Patients with Drug-Induced Thrombocytopenia. *Transfusion* 2005; 45 (3S) 134A.
21. Ely P, Stearns DM, Zaki BI, Fitzmaurice TF, Gautier M, Lowrey CH, Bengtson EM, Hill JM, Schaal AD, Kimitis EA, Root L, Webber S, Szczepiorkowski ZM, Meehan KR. Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma (NHL). [Abstract] *Blood* 2005; 106(11), Part 2 of 2, 467b.
22. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Maes L, Marques MB, Sarode R, Schwartz J, Shaz B, Weinstein R, Wirk A, Winters J. A New Approach to Assign ASFA Categories for Therapeutic Apheresis Indications. *J Clin Apheresis* 2006;21:1. Plenary presentation.
23. McGregor DJ, Lamson CA, Swain JL, Klinker K, Szczepiorkowski ZM. Quality of MNC Collections – Can It Be Improved by Providing a Direct Feed-Back to Collection Personnel. *J Clin Apheresis* 2006;21:9.

24. Hill ET, Jauss KZ, Conklin J, McGregor DJ, Lamson CA, Szczepiorkowski ZM. The Long Term Use of Therapeutic Plasmapheresis in the Patient with Catastrophic Antiphospholipid Syndrome. *J Clin Apheresis* 2006;21:32.
25. Webber SM, Peront AL, Fisher JL, Ernstoff MS, Szczepiorkowski ZM. Comparison of the Effect of Monocyte Enrichment Using Elutriator, Elutra and ClinicMACS on Monocyte Derived Dendritic Cells Transfusion 46, (9s); 59A.
26. Webber SM, Peront AL, Fisher JL, Ernstoff MS, Szczepiorkowski ZM. Comparison of three cell separation devices for monocyte enrichment from leukapheresis products. *Transfusion* 2006; 46, (9s): 59A.
27. Webber SM, Szczepiorkowski ZM. Transition from the Research Laboratory to the Clinical Laboratory in Cellular Therapy: The Use of Project Plan Management *Transfusion* 2006; 46, (9s); 230A.
28. Meyer EK, Klinker K, Szczepiorkowski ZM, AuBuchon JP. Platelet donor screening for aspirin effect. *Transfusion* 2006;46, (9s); 85A.
29. Hill JM, Wu J-Y, Webber SM, Sharlin O, Kendall M, McGregor D, Ernstoff MJ, Szczepiorkowski ZM, and Meehan KR. Immune Mobilization of Autologous Peripheral Blood Progenitor Cells: IL-2 with GM-CSF and G-CSF Results in Effective Mobilization without Delay in Engraftment. *Blood (ASH Annual Meeting Abstracts)*, Nov 2006; 108: 5152.
30. Wu J-Y, Webber SM, Hill JM, Ernstoff M, Szczepiorkowski Z, and Meehan KR. Large Scale Expansion of Activated T Cells: Defining Procedures and Cryopreservation Methods for Clinical Use as Adoptive Cellular Therapy Post-Transplant. *Blood (ASH Annual Meeting Abstracts)*, Nov 2006; 108: 5232.
31. Ely P, Stearns DM, Zaki BI, Fitzmaurice TF, Gautier M, Lowrey CH, Bengtson EM, Hill JM, Schaal AD, Kimitis EA, Root L, Webber S, Szczepiorkowski ZM, and Meehan KR. Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma (NHL). *Blood (ASH Annual Meeting Abstracts)*, Nov 2006; 106: 5517.
32. Hill JM, Wu J-Y, Webber S, Sharlin O, Ernstoff MS, Szczepiorkowski ZM, Meehan KP. HImmune Mobilization of Autologous Peripheral Blood Progenitor Cells: IL-2 with GM-CSF and G-CSF Results in Effective Mobilization without Delay in EngraftmentH. *Biol Blood and Marrow Transplantation – 2007*
33. Meehan KP, Bengtson E, Wu J-Y, Ely P, Hill JM, Szczepiorkowski ZM, Ernstoff M. Immunotherapy Immediately Following Transplantation for Multiple Myeloma: Early Recovery of Aggressive Cytotoxic Cells and Improved Immune ResurgenceH. *Biol Blood and Marrow Transplantation – 2007*

34. Meyer EK, McGregor DJ, Schaal AD, Gautier M, Szczepiorkowski ZM. Development of ADAMTS-13 Inhibitor in a Patient with Relapsing TTP-Natural History or Iatrogenic Effect. *J Clin Apheresis* 2007;22 (2):56.
35. Meyer EK, McGregor DJ, Szczepiorkowski ZM. Therapeutic Plasma Exchange in Steroid Resistant Multiple Sclerosis – One Center’s Experience (2001-2006). *J Clin Apheresis* 2007;22 (2):55 – Dr. Meyer received the best abstract in neurology 2007 and presented during the abstract plenary session.
36. Meyer EK, McGregor DJ, Szczepiorkowski ZM. Measured Hemoglobin in HPC, Apheresis Products Does Not Reflect Red Blood Cell Content. *Transfusion* 2007;47 Suppl;61A.
37. Marques MB, Andrzejewski C, Downes K, Hofmann J, Leung S, Shaz B, Shelat S, Szczepiorkowski Z, Troughton M, Weinstein R, Winters J. Assessing the Quality of Practice in Apheresis Medicine. *J Clin Apheresis* 2008;23:5-6.
38. Shaz BH, Brecher M, Li Y, Mair D, Marshall C, Sachais B, Sarode R, Schwartz J, Shelat S, Weinstein R, Winters J, Szczepiorkowski Z, Andrzejewski C. Addressing Challenges in Resident and Fellow Training in Apheresis Medicine. *J Clin Apheresis* 2008;23:15.
39. Klinker K, Kidder R, Szczepiorkowski ZM. Impact of a Standalone Hematology Analyzer on Platelet Collections in a Small Apheresis Donor Center. *J Clin Apheresis* 2008;23:36-37.
40. Grindle K, Marx-Wood C, Szczepiorkowski Z. Flu Season and Anti-A and Anti-B Titers in Group O Platelets. *Transfusion* 2008 48:Suppl: 257A. (oral presentation)
41. Cooper LK, Szczepiorkowski Z, Dumont LJ, AuBuchon JP. Prospective Evaluation of Three Protocols to Integrate a Rapid Bacterial Detection System into Routine Daily Operations in a Mid-Sized Transfusion Safety Laboratory. *Transfusion* 2008 48 Suppl: 209A
42. Weber SM, Peront AL, RuoffKL, Szczepiorkowski ZM. Cellular Therapy Product Microbial Contamination – How effective is the detection system? *Cytotherapy* 2009;11(1):47.
43. Kreuter J, Klinker K, Szczepiorkowski ZM. Deferral of Apheresis Platelet Donors Based on the Presence of HLA Antibodies – A Survey of Emotional Impact. *Transfusion* 2009; 49(Supplement):256A
44. Meyer E, Maynard KJ, Szczepiorkowski Z. Evaluation of the Quality of Recovered Autologous Blood Using Haemonetic’s OrthoPAT System®: A Preliminary Retrospective Study. *Transfusion* 2009; 49(Supplement):168-69A
45. Pamphilon D, Selogie E, Szczepiorkowski Z. Transportation of Cellular Therapy Products: A Worldwide Survey of Collection and Processing Sites. *Transfusion* 2009; 49(Supplement):174-75A

46. Chen H, Hill J, Szczepiorkowski Z. Passively Acquired HBc and HTLV I/II Antibodies from Intravenous Immunoglobulin Therapy in a HSCT Patient. *Transfusion* 2009; 49(Supplement):179A
47. Kreuter J, Klinker K, Lamson CA, Hofmann C, Szczepiorkowski Z. Apheresis Platelets Collected from Subsequentially Deferred Donors Based on the Presence of HLA Antibodies Do Not Present Increased Risk of Transfusion Reactions, but Deferral Negatively Impacts Supply. *Transfusion* 2009; 49(Supplement):196A
48. Talebian LX, Fischer DA, Szczepiorkowski ZM, Sentman CL, Meehan KR. The Critical Requirement of the NKG2D Receptor on CD8+ T Cells in Killing Myeloma Cells. *Blood* (ASH Annual Meeting Abstracts), Nov 2009;114:4733. Publication only
49. Shah RM, Szczepiorkowski ZM, Leach MK, Zuckerman RA. The Significance of Anti-Platelet Antibodies Associated with Antibiotic Use, A Descriptive Analysis. *Blood* (ASH Annual Meeting Abstracts), Nov 2009;114:4470 Publication only
50. Bejarano Varas MT, Robert D, Szczepiorkowski ZM. Acquired von Willebrand's Syndrome Secondary to Waldenstrom's Macroglobulinemia – Role of Therapeutic Plasma Exchange. *J Clin Apheresis* 2010;25(1):20
51. Klinker K, Didehbani T, Stankiewicz K, Szczepiorkowski ZM. Pityriasis Rubra Pilaris – Should Extracorporeal Photopheresis be Considered. *J Clin Apheresis* 2010;25(1):31
52. Klinker K, Hofmann C, Szczepiorkowski ZM. Successful Treatment of Exacerbation of Catastrophic Antiphospholipid Syndrome with Therapeutic Plasma Exchange. *J Clin Apheresis* 2010;25(1):35
53. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, Jones M, Christoffel T, Pelham E, Slichter SJ. A Randomized Controlled Trial Comparing Autologous Radiolabeled in Vivo Platelet Recoveries and Survivals of 7-Day Stored PRP and Buffy Coat Platelets from the Same Donors. *Transfusion* 2010;50(2S):1-2A (plenary session)
54. Cancelas J, Rugg N, Dumont LJ, Szczepiorkowski ZM, Siegel AH, Erickson A, Propst M, North AK, Mufti N, Corash L. Comprehensive Evaluation of a New Process for S-303 Pathogen Inactivation of Red Blood Cells. *Transfusion* 2010;50(2S):9-10A
55. Dumont LJ, Dumont DF, Herschel LH, Baker S, Housman ML, Waters SL, Ransom JH, Siegel A, Szczepiorkowski ZM, Michael RA. A Randomized Controlled Trial Comparing in Vivo Recovery and Survival of DMSO Cryopreserved Autologous Platelets to Fresh Platelets in Healthy Volunteers. *Transfusion* 2010;50(2S):42A
56. Razatos A, Snyder EL, Wilson KM, Baril L, Dumont DF, Herschel LH, Wittevrongel L, Fender L, Szczepiorkowski ZM, Dumont LJ. In Vivo Radiolabeled Recovery and Survival of Platelets Stored in a New Platelet Additive Solution for 5 Days Compared to Fresh Platelets. *Transfusion* 2010;50(2S):64A

57. Kreuter J, Leach M, Ornstein D, Szczepiorkowski ZM. Introduction of IgG-specific Assay Decreases the Rate of Borderline Positive Results in Patients Clinically Suspected for Heparin Induced Thrombocytopenia. *Transfusion* 2010;50(2S):125A
58. Reems J, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Nielsen D, Yuan N, Nawrot M. An Inter-Laboratory Study to Evaluate a Novel Colony Forming Unit (CFU) Assay that Requires Only 7-Days of Culture. *Transfusion* 2010;50(2S):217A
59. Shaz B, Szczepiorkowski ZM, Crawford JM, Black-Schaffer WS, Winters JL. Survey Results Regarding Implementation of the Transfusion Medicine Fellowship Match. *Transfusion* 2010;50(2S):239-240A
60. Maynard KJ, Leach M, Lambert LT, Marx-Wood C, Barna JA, Szczepiorkowski ZM. Heeding the Voice of Transfusionist: Label Redesign for Safer Bedside Blood Checking. *Transfusion* 2010;50(2S):274A
61. Dumont LJ, Cancelas J, Maes LY, Whitley PH, Szczepiorkowski ZM, Siegel AH, Herschel L, Calgagni KE, Waters SL, Zia M. Storage in an Experimental Additive Solution Enables Overnight Room Temperature Hold of Whole Blood Prior to Processing. *Transfusion* 2011;51(3S):42A
62. Dumont LJ, Szczepiorkowski ZM, Siegel AH, Herschel L, Calgagni KE, Waters SL, Yoshida T. Performance of Anaerobic Stored Red Blood Cells Prepared using a Prototype O₂ and CO₂ Depletion and Storage System. *Transfusion* 2011;51(3S):76A
63. Petras ML, Leach MK, Szczepiorkowski ZM, Dunbar NM. Red Blood Cell Antibodies: A 45 Year Historical Review at a Rural Tertiary Care Center. *Transfusion* 2011;51(3S):160A
64. Reems J, Pamphilon DH, Szczepiorkowski ZM, Selogie EA. Current Practices for the Colony Forming Cell (CFC) Assay: Report of a Survey by the Cellular Therapies Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. *Transfusion* 2011;51(3S):224A.
65. Burnett CA, Parenti D, Birbeck KA, Abhyankar S, Lewis DK, Szczepiorkowski ZM, Dumont LJ. A Phase I Healthy Volunteer Exploratory Study to Assess Induction of Apoptosis Associated with the Therakos™ UVAR™ XTST™ System. *J Clin Apheresis* 2011;26(2):62-63
66. Klinker K, Szczepiorkowski ZM, Dunbar NM. Nurses Love It. An Optimized Tool to Predict HPC(A) Collection Yield. *J Clin Apheresis* 2012;27(1):17
67. Didehbani TS, Martin CLB, Szczepiorkowski ZM, Dunbar NM, Klinker K. Nurse's Perspective on Symptom Management of Citrate Toxicity During Extracorporeal

Photopheresis where Acid Citrate Dextrose (ACD-A) is Used As Anticoagulant. J Clin Apheresis 2012;27(1):22

68. Cancelas J, Dumont LJ, Maes LY, Rugg N, Herschel L, Whitley PH, Pratt PG, Szczepiorkowski ZM, Wellington M, Zia M. RBC Storage in SOLX® Additive Solution Ameliorated the Storage Lesion and Demonstrated Extended Storage up to 56 Days: Results of a Multicenter Trial. Transfusion 2012;52(3S):47A
69. Cancelas J, Dumont LJ, Maes LY, Rugg N, Herschel L, Whitley PH, Hartman EL, , Szczepiorkowski ZM, Sawyer S, Zia M. Frozen Plasma Prepared with SOLX® System from WB Held at Room Temperature for 24 Hours Was Bioequivalent to FFP Except for Factor VIII. Transfusion 2012;52(3S):53A
70. Weber LL, Maynard K, Szczepiorkowski ZM, Dunbar NM. Acetaminophen Pre-medication Decreases Temperature Elevation in Febrile Non-hemolytic Transfusion Reactions. Transfusion 2012;52(3S):179A
71. Dunbar NM, Walsh SJ, Freeman CM, Szczepiorkowski ZM. Increased Risk for Specimen Mislabeling in the Emergency Department Following Electronic Medical Record Implementation and the Impact of Provision of Type O Blood to Patients Without Historic ABO Type. Transfusion 2012;52(3S):197A.
72. Dunbar NM, Kreuter J, Marx-Wood CR, Dumont LJ, Szczepiorkowski ZM. Bacterial Screening of Apheresis Platelets with a Rapid Test - A 4 Year Single Center Experience. Transfusion 2012;52(3S):204A
73. Schwartz J, Szczepiorkowski Z, Delaney M, Winters J, Linenberger M, Wu Y, Balogun R, Padmanabhan A, Williams M, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach. J Clin Apheresis 2013;28(2):94
74. Martin CLB, Szczepiorkowski ZM, Dunbar NM. Complete Recovery of Neurologic Function in a Patient with Marburg's Variant of Multiple Sclerosis who Received High Dose Cyclophosphamide and Therapeutic Plasma Exchange. J Clin Apheresis 2013;28(2):127
75. Yerrabothala S, Desrosiers KP, Szczepiorkowski ZM, Dunbar NM. Decreasing Inappropriate Two-Unit Red Blood Cell (RBC) Transfusions with a Restrictive Transfusion Policy. Transfusion 2013; 53 (2S):56A
76. Desrosiers KP, Yerrabothala S, Szczepiorkowski ZM, Dunbar NM. Reduction in Inappropriate Red Cell Transfusion through Prospective Computerized Order Auditing. Transfusion 2013; 53(S2):237A
77. Katus MC, Martin CLB, Szczepiorkowski ZM, Gorham JD, Dunbar NM. Rapid ADAMTS13 Availability Impacts Treatment for Microangiopathic Hemolytic Anemia and

- Thrombocytopenia. *J Clin Apheresis* 2014;29(1):2-3 (Abstract 3; Katus MC – Junior Investigator Award)
78. Patel P, Cooling L, Kiss J, Sachais B, Sarode R, Schwartz J, Szczepiorkowski ZM, Wu Y, Wong E, Perumbeti A. A Gap Analysis of Research in Apheresis-Knowledge Gained from Systematic Review of Clinicaltrials.gov. *J Clin Apheresis* 2014;29(1):3-4. (Plenary Session)
79. Szczepiorkowski ZM, Min K, Radwanski K, Winters JL. The Future of Research and Practice of Extracorporeal Photopheresis – Heterogeneity in Expert Panel Opinion. *J Clin Apheresis* 2014;29(1):14.
80. Wu Y, Alsammak M, Altuntas F, Frenk A, Klingel R, Smid M, Vrielink H, Witt V, Szczepiorkowski ZM. An Opportunity for Standardization and Collaboration among Apheresis International Community: The Report of the ASFA International Affairs Committee. *J Clin Apheresis* 2014;29(1):15.
81. Didehbani TS, Martin CLB, Hofmann C, Dunbar NM, Szczepiorkowski ZM. A Nursing Educational Tool to Improve Quality of Care in Patients Receiving Extracorporeal Photopheresis. *J Clin Apheresis* 2014;29(1):19-20.
82. Martin CLB, Dunbar NM, McGregor D, Szczepiorkowski ZM. ECP Procedure Failures: Is There an Acceptable Frequency? *J Clin Apheresis* 2014;29(1):20-21.
83. Martin IW, Martin CLB, Lee SL, Dunbar NM, Szczepiorkowski ZM. Therapeutic Plasma Exchange as a Steroid-Sparing Therapy in a Patient with Limbic Encephalitis due to Antibodies to Voltage-Gated Potassium Channels. *J Clin Apheresis* 2014;29(1):47-48.
84. Worsham DN, Hartman EL, Reems J, Szczepiorkowski ZM, McKenna D, Matthew A, Cancelas J. Cryopreservation of Donor Lymphocyte Clinical Products with Conventional 10% DMSO Results in Reduced T Helper and T Reg Viability and Proliferation upon Stimulation, Compared with Alternative Conventional Methods: Results of a Multicenter Trial. *Transfusion* 2014;54; No 2S, September 2014 Supplement:64A
85. Radwanski K, Dumont JL, Herschel L, Waters SL, Szczepiorkowski ZM, Siegel AH, Min K. New RBC Additive Solution Reduces Storage Hemolysis while Maintaining in vivo Performance. *Transfusion* 2014;54; No 2S, September 2014 Supplement: 50A.
86. Martin CLB, Dunbar NM, Hofmann C, Szczepiorkowski ZM. A Re-Evaluation of the Failure Rates of the UVAR XTS and CELLEX Devices Used for Extracorporeal Photopheresis. *J Clin Apheresis* 2015;30(1):87
87. Hewitt BA, Defoe GR, Dunbar NM, Szczepiorkowski ZM. Can We Do it Right? Implementation of a Perioperative Documentation Training Program. *Transfusion* 2015;55; September 2015 Supplement 3: 205A

88. Martin I, Szczepiorkowski ZM, Dunbar NM. Are Group O Donors More Likely to Make anti-HLA Antibodies than Non-Group O Donors? *Transfusion* 2015;55; September 2015 Supplement 3:97A
89. Dunbar N, Raval J, Adamski J, Cooling L, Grossman B, Kim HC, Morgan S, Sloan S, Szczepiorkowski Z, Wong E, Schneiderman J. Extracorporeal Photopheresis Practice Patterns: an International Survey by the ASFA ECP Donor Subcommittee. *J Clin Apheresis* 2016;31(2):74
90. Alquist CR, Root L, Dunbar N, Szczepiorkowski Z. Cautionary Tales for Apheresis Professionals: Healthy Donors and Disappearing White Cells. *J Clin Apheresis* 2016;31(2):91
91. Alquist CR, Szczepiorkowski Z, Dunbar N. Rapid Increase in Babesia Parasitemia Following RBC Exchange. *J Clin Apheresis* 2016;31(2):99
92. Alquist CR, Johnson K, Geiser A, Szczepiorkowski Z. Pediatric Therapeutic Plasma Exchange: Explaining the Big Picture to Little Patients. *J Clin Apheresis* 2016;31(2):120
The poster received THE BEST POSTER AWARD at the ASFA meeting, Palm Springs, CA.
93. Klinker K, Ajavon E, Szczepiorkowski ZM. Effective Recruitment Strategies at a Rural Hospital-Based Donor Center. *Transfusion* 2016;56; September 2016 Supplement 34:93A
94. Szczepiorkowski Z, Slaper-Cortenbach I, Distler P, Ashford P. Simultaneous Implementation of the Single European Code and ISBT 128. EBMT 2016 Poster
95. Szczepiorkowski Z, Slaper-Cortenbach I, Distler P, Ashford P. Standardized Terminology for Source Organs, Cellular Therapy, and Regenerated Tissues. ISCT 2016 Poster
96. Coker S, Szczepiorkowski ZM, Seigel AH, Ferrari A, Benatti L, Mambrini G, Anand R, Hartmann RD, Dumont LJ. The In Vivo Recovery/Survival and Pharmacokinetic Properties of Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes. *Blood* 2016 128:2629
97. Slichter SJ, Dumont LJ, Cancelas JA, Gernsheimer T, Szczepiorkowski Z, Dunbar NM, Medlin S, Jones ML, Rugg N, Prakash G, Housler GJ, MacDonald VM, Hmel P, Ransom JH. Treatment of Bleeding in Severely Thrombocytopenic Patients with Transfusion of Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP) is Safe – Report of a Phase 1 Dose Escalation Safety Trial. *Blood* 2016 128:1030
98. Martin C-LB, Ward-Roberts P, Didehbani TS, Szczepiorkowski ZM. Natural Course of Anemia Among Chronic GvHD Patients Undergoing ECP. *J Clin Apheresis* 2017;32(2):79
99. Martin C-LB, Ward-Roberts P, Szczepiorkowski ZM. Heterogeneity in Transfusion Requirements for Patients Receiving ECP. *J Clin Apheresis* 2017;32(2):81

100. Martin C-LB, Martin I, Szczepiorkowski ZM. Is There Optimal Vascular Access for Pediatric Patients Undergoing Chronic Red Cell Exchange. *J Clin Apheresis* 2017;32(2):100
101. Martin I, Maloney N, Szczepiorkowski ZM, Dunbar NM. Use of ADAMTS13 Activity and Inhibitor Level to Guide Therapeutic Plasma Exchange Therapy in a Refractory Patient. *J Clin Apheresis* 2017;32(2):118
102. Dunbar NM, Szczepiorkowski ZM. Bacterial Screening of Apheresis Platelets with a Rapid Test – an 8 Year Single Center Experience. *Transfusion* 2017;57; September 2017 Supplement S3: 61A
103. Gray AD, Landrigan M, Whitley P, Wellington M, Sawyer S, Hanley S, Rondeau E, Herschel L, Rugg N, Bruncker PAR, Nestheide S, Cancelas-Perez J, Dumont L, Szczepiorkowski ZM. In Vitro Quality of Rejuvenated and Washed CPD/As-1 and CP2D/As-3 RBC. *Transfusion* 2017;57; September 2017 Supplement S3: 85A
104. Klinker K, Dunbar NM, Szczepiorkowski ZM. Whole Blood Leukoreduction Failures – Following Manufacturer’s Instructions May Not be Enough. *Transfusion* 2017;57; September 2017 Supplement S3: 95A
105. Dunbar NM, Szczepiorkowski ZM. Increased Patient Safety and Improved Inventory Management with 7 Day Apheresis Platelets. *Transfusion* 2017;57; September 2017 Supplement S3: 194A
106. Wu Y, Perumbeti A, Li A, Quirolo K, Balogun R, Dunbar N, Schwartz J, Winters JL, Witt V, Szczepiorkowski Z, Onwuemene T. Establishment of the ASFA Therapeutic Apheresis Outcomes System (TAOS). *J Clin Apheresis* 2018;33(2):154.
107. Martin CLB, Didehbani TS, Hofmann CM, Szczepiorkowski ZM. To Check or Not to Check? Standardization of Testing Fibrinogen Levels in Therapeutic Plasma Exchange Patients. *J Clin Apheresis* 2018;33(2):165.
108. Linnik YA, Moiseff R, Thomasson R, Szczepiorkowski Z, Dunbar N. Iatrogenic Hypoglobulinemia due to the Therapeutic Plasma Exchange: Managing the Patient with Allergies to Blood Products. *J Clin Apheresis* 2018;33(2):191.
109. Fontaine MJ, Selogie E, Stroncek DF, McKenna DH, Szczepiorkowski ZM, Reems J-A. Variations in Novel Cellular Therapy Products Manufacturing. *Transfusion* 2018, 58; September 2018, Supplement S2:74A
110. Plumier L, Martin CLB, Baker S, Foster C, Szczepiorkowski ZM. Lower Neutrophil Counts in Autologous HPC, Apheresis Products Correlate with Improved Cell Viability at Thaw. *J Clin Apheresis* 2019;34(2):125.

/// additional abstracts from 2020-2024

Presented at International Meetings:

1. Szczepiorkowski ZM, Doyle KM, Trace V, and Laposata M. Fatty acid ethyl esters in reconstituted LDL particles are toxic to intact Hep G2 cells. First International Congress of the ISSFAL (International Society for the Study of Fatty Acids and Lipids), Lugano, Switzerland, June 30-July 3, 1993
2. Teruya J, Cluette-Brown J, Szczepiorkowski ZM, and Laposata M. Mode of transport of fatty acid to endothelial cells influences intracellular fatty acid metabolism. First International Congress of the International Society for the Study of Fatty Acids and Lipids, Lugano, Switzerland, June 30-July 3, 1993
3. Laposata M, Doyle KM, Szczepiorkowski ZM, Gorski N, and Goss KA. Fatty Acid Ethyl Esters as a causative agent in ethanol-induced organ damage: biochemical and clinical studies. First International Congress of the International Society for the Study of Fatty Acids and Lipids, Lugano, Switzerland, June 30-July 3, 1993

Updated by: Zbigniew M. Szczepiorkowski, MD, PhD

Date: March 28, 2024